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1. INTRODUCTION 
1.1 Psoriasis 
Our skin connects and at the same time separates the internal and the external environment. 
It is constantly subjected to many different stimuli that require proper responses, through 
which the skin can influence the function of other organs, like the brain and the endocrine 
system in a mutual way
1,2
. 
Psoriasis is a chronic inflammatory skin disease, mainly characterised by abnormalities in 
the immunological response of the skin to various internal and external stimuli
3
. It affects 
approximately 2% of the human population world-wide with no gender differences
4
. The age 
of onset is typically between 20-30 years (early-onset) or 50-60 years (late-onset)
5
. The most 
common form (90%) is plaque-type psoriasis characterised by erythematous plaques with 
silvery scales, mainly on the extensor surfaces of the extremities, scalp, sacrum and 
umbilicus
4
. On histological sections of psoriatic plaques, elongated rete ridges, 
hyperkeratosis, parakeratosis and Munro’s microabscesses can be found with dilated vessels 
in the dermal papilla
6
. The exact cause of psoriasis is unknown, however, genome-wide 
association studies (GWAS) have identified over 50 regions associated with the risk of the 
disease. The coding genes of these regions are connected to antigen presentation, the 
interleukin-23 (IL-23) axis, T-cell development and polarisation, innate immunity and 
negative regulators of immune responses
7
. Psoriasis is not only a skin disorder; it is associated 
with systemic inflammation
8
. Comorbid conditions are psoriatic arthritis, Crohn’s disease, 
cancer, depression, non-alcoholic fatty liver disease, metabolic syndrome and cardiovascular 
disorders
9
. To date, all therapies available for psoriasis only manage symptoms. 
Understanding alterations behind the disease is crucially important for developing new 
therapies for better disease management. 
1.1.1 Biomarkers in psoriasis 
Previous large-scale treatises including genomic, transcriptomic and proteomic studies 
have identified psoriasis-related markers playing key roles in the pathomechanism, such as 
AKR1B10
10
, CSTA
11
, FABP5
12
, PI3
13
, SCCA2
14
, STAT1
10
, STAT3
15
, S100A2
16
, S100A7
12–
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14
, S100A8
13,17
 and S100A9
13,14,17,18
, among others, thereby contributing greatly to better 
understanding of the disease. 
Several proteomic studies have led to biomarker discovery contributing to the diagnosis or 
the estimation of prognosis in psoriasis. According to Williamson et al., among proteins with 
altered levels in psoriatic lesional vs. non-lesional skin, profilin 1 showed a tendency to 
increase in the plasma of psoriatic patients
12
. Fibrinogen α-chain-derived peptide and a 
filaggrin-derived peptide were found to be increased in the sera of patients with psoriasis 
vulgaris and psoriatic arthritis compared to those of healthy individuals
19
. Patients with 
psoriasis could be differentiated from those with atopic or contact dermatitis by the serum 
level of kynureninase
20
. Desmoplakin, complement C3, polymeric immunoglobulin receptor 
and cytokeratin 17 plasma levels were significantly altered compared to healthy controls and 
correlated with the Psoriasis Area Severity Index (PASI) score
21
. 
1.1.2 Proteomic studies of the psoriatic skin 
One of the most effective ways to study different diseases with such enormous complexity 
and to elucidate related mechanisms is to perform a comparative proteomic analysis of protein 
extracts derived from affected tissues. 
A recent review summarised the novel mechanisms and hypotheses proposed by the results 
of proteomic studies of psoriasis
22
. In the articles reviewed, the following results are related to 
the alterations of the psoriatic skin: I. Proteins showing increased expression in psoriatic 
lesional skin were related to abnormalities in cell proliferation, the regulatory/balancing 
system and inflammation
23
. II. S100A8, S100A9 and complement C3 were upregulated in 
lesional vs. non-lesional skin
17
, while kallikrein-related peptidase 6, solute carrier family 25, 
cystatin A and serpin B1
11
 were increased in psoriatic lesions compared to healthy skin. III. 
Lysvand and colleagues found that unique epitopes on the Pso p27 complex caused by the 
post-translational modification of Serpin B3 (SCCA1) may be immunogenic in psoriasis
24
. 
IV. Some proteins with differential expression in lesional vs. non-lesional skin were targeted 
by IL-17A
25
, while others were related to mechanisms contributing to abnormal epidermal 
growth
26
. 
Until now, none of the full-scale psoriatic proteomic studies
11,12,17,20,23,26,27
, to the best of 
our knowledge, have compared lesional and non-lesional psoriatic skin regions (both 
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epidermis and dermis) with the inclusion of biopsies from healthy individuals as a reference 
in the comparison. The inclusion of healthy skin could provide several pieces of important 
additional information. I. Alterations that are similar in non-lesional and lesional skin, but 
differ from healthy skin, can be detected and used to identify potential novel disease markers 
or predisposing factors already present in the non-lesional skin. II. The comparison of non-
lesional skin to healthy skin might facilitate the identification of inherent characteristics of 
psoriatic patients that are already present in their healthy-looking skin prior to lesion 
development. III. Information could be gained about the extent to which the non-lesional skin 
is affected with respect to lesional alterations. IV. Altered processes in the non-lesional skin 
that are contrary to the changes of lesional skin could be identified, some of which may 
contribute to the maintenance of the non-lesional state and serve as novel intervention points 
for disease management. 
1.1.3 The psoriatic non-lesional skin 
In psoriasis, the macroscopically healthy-looking non-lesional skin harbours alterations 
that might cause symptoms
28
. One of the most characteristic properties of the non-lesional 
skin is an altered response to mechanical stress or injury
29
 leading to barrier disruption
30
, 
which leads to an elevated innate immune response
31,32
. Alterations in non-lesional skin are 
not restricted to keratinocytes. Angiogenesis is also among those mechanisms that are already 
affected in the non-lesional skin, resulting in altered quantity and quality of microvessels
33
. In 
addition, it is becoming clear that some adaptive immune responses are also altered
34
. 
Abnormalities in the dermal extracellular matrix composition, such as elevated expression of 
the oncofetal splice variant of fibronectin
35
 due to altered splicing events
36
, indicate the 
involvement of dermal fibroblasts
28
. Several matrix metalloproteinases (MMPs), such as 
MMP-9, previously thought to be increased only in lesions, are now known to be elevated in 
non-lesional skin compared to healthy skin
37
. There is also evidence for mechanisms in non-
lesional skin that contribute to the maintenance of its state. The PRINS long non-coding RNA 
is induced by stress and nucleic acids, and it is anticipated to have a protective function in 
psoriasis. Not only does PRINS decrease inflammatory responses
38
 in the non-lesional skin by 
inhibiting IL-6 and chemokine (C-C motif) ligand 5 (CCL-5) mRNA translation, but it also 
influences anti-apoptotic mechanisms
39
. The elevated expression of the anti-inflammatory 
12 
 
regulator caspase recruitment domain family member 18 (CARD18) in non-lesional skin 
compared to healthy skin was found to aid the inhibition of inflammatory events
40
. These 
mechanisms, among many others, highlight the relevance of comparing non-lesional skin to 
healthy skin. 
The psoriatic non-lesional skin is characterised by increased stress response to several 
external and internal factors, such as mechanical stress
29
 and alcohol
41–44
, which results in 
plaque formation. The central features of psoriatic plaque formation include abnormal 
keratinocyte proliferation and differentiation leading to the disturbance of the barrier function 
of the skin, among others. 
1.2 Impaired barrier function of the skin and related osmotic challenge 
Impaired barrier function is the main pathologic finding in irritant contact dermatitis 
(ICD), resulting in increased skin permeability and transepidermal water loss (TEWL)
45
. 
Water evaporation can lead to a higher osmotic pressure in the superficial layers of the skin, 
therefore local hyperosmotic challenge may contribute to the development of the disease. 
Hyperosmolarity reduces cellular viability
46–50
 and elevates intracellular calcium (Ca
2+
) 
concentration in HaCaT keratinocytes. Although its exact molecular mechanism has not yet 
been revealed, it has been shown that Ca
2+
 is derived from both intra- and extracellular 
compartments
49,51
. 
Osmotic stress induces further intracellular responses. At mRNA level, the expression of 
tumour necrosis factor-alpha (TNF-α), IL-1β, IL-846, IL-647 and the nuclear factor of activated 
T cells 5 (NFAT5)
48
 was found to be higher in epithelial cells under hyperosmotic condition. 
Elevated mRNA expression of TNF-α, IL-1β, IL-6 and IL-8 was also observed in normal 
human epidermal keratinocytes
52
. 
NFAT5 is a principal transcription factor involved in water homeostasis during normal 
cornification
53
 and activated by hyperosmotic stress
48
, however, its regulation by Ca
2+ 
signals 
is equivocal
54–56
. Local hyperosmotic stress of the skin activates NFAT5 in macrophages
57
, 
thereby intensifying the electrolyte clearance via lymphatic vessels
58
. 
Under experimental conditions, different methods are used to induce hyperosmotic stress. 
Sodium chloride is usually used for this aim
46–48 
and non-ionic organic agents such as 
sorbitol
52
 and sucrose
47
 can also be applied on keratinocyte cultures. 
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1.3 Beneficial effects of polyols on the skin 
Glycerol and xylitol have well-known beneficial effects on the skin
59–62
.
 
Previously, we 
have shown their anti-inflammatory and anti-irritant effects
60–62
. Other in vitro experiments 
have revealed that glycerol suppresses human leukocyte antigen-DR (HLA-DR) mRNA 
level
63
, while xylitol inhibits inflammatory cytokine expression
64
 and upregulates filaggrin 
mRNA expression
63
. In addition, glycerol is known to compose the principal osmolyte system 
of several bacterial species
65
. However, the role of glycerol and xylitol as osmolytes in the  
skin has not yet been fully clarified.
14 
 
2. AIMS 
We aimed to extend previous proteomic studies, in order to get more information regarding 
the putative alterations in psoriasis. Therefore, a complex comparison was performed, where 
in addition to non-lesional and lesional skin, samples from healthy skin were also included, in 
a label-free, semi-quantitative proteomic analysis. 
Furthermore, we aimed to investigate whether glycerol and xylitol, as known effective 
anti-irritant agents
60–62
, provide protection against hyperosmotic stress in vitro. Their effects 
on cellular viability, cytotoxicity, intracellular Ca
2+
 concentration and expression of pro-
inflammatory cytokines were studied in hyperosmotic condition. 
15 
 
3. MATERIALS AND METHODS 
3.1 Patients and skin sample collection 
Skin biopsy collection from donors, the procedure of collection and all experimental 
protocols were approved by the Regional and Institutional Research Ethics Committee and by 
the Human Investigation Review Board of the University of Szeged (SOEDAFN-002, IF-562-
5/2016 and IF-15056/2015; 157/2015; 3638 and 2799, 3517), strictly following the guidelines 
and regulations of the Declaration of Helsinki. Prior to surgical intervention and following a 
detailed description of the skin biopsy donation procedure, participants provided written 
informed consent. No donor under the age of 18 was included in our study. 
To identify alterations that are general in chronic plaque psoriasis and to keep the number 
of volunteers for skin biopsy collection to a minimum, for our proteomic approach, we 
randomly engaged individuals I.) of different age to minimise possible age-related 
differences; II.) with various PASI scores between 5 and 25 since the score for an individual 
patient varies over time and with relapse; III.) of both genders to avoid possible gender-
associated differences; and IV.) with both early and late onset. A total of 9 (3x3) patients 
suffering from chronic plaque psoriasis and the same number of healthy donors were involved 
in our study. None of the psoriatic patients had received any kind of treatment for the 
condition for at least 6 months. 6 mm skin punch biopsies containing the epidermis and the 
dermis were collected from an area of the upper-middle gluteal region that is not exposed to 
sunlight. Both lesional and non-lesional samples were collected from patients. Non-lesional 
samples were taken at least 7 cm from the edge of the lesion subjected for biopsy. The 
presence of psoriasis was clinically verified for all patients, and clinical as well as 
demographic data of the donors are presented in Table 1.
16 
 
Proteomic 
experiment 
Group of 
donors 
Donors Age Gender 
PASI 
score 
No. 1 
Healthy 
H I. 46 
Male 
n/a H II. 59 
H III. 51 
Plaque-type 
psoriasis 
P I. 65 17.1 
P II. 63 9.9 
P III. 50 5.5 
No. 2 
Healthy 
H IV. 23 
Female 
n/a H V. 48 
H VI. 51 
Plaque-type 
psoriasis 
P IV. 25 9.2 
P V. 62 21.5 
P VI. 70 17.5 
No. 3 
Healthy 
H VII. 37 
Male 
n/a H VIII. 39 
H IX. 61 
Plaque-type 
psoriasis 
P VII. 49 22.4 
P VIII. 55 12.1 
P IX. 61 12 
Table 1. Basic demographic and clinical characteristics of donors involved in the proteomic 
analysis (H: healthy donor, P: plaque-type psoriatic patient, PASI: Psoriasis Area Severity Index, n/a: 
not available) 
3.2 Comparative proteomic workflow of healthy, non-lesional and lesional skin 
3.2.1 Four-step sequential protein extraction 
Samples were cut with a razor blade. Skin proteins were extracted sequentially in four 
consecutive, solubility-based extraction steps. Extraction buffers were used in increasing 
order of their solubilising properties for a better separation of proteins. Samples were initially 
incubated in extraction buffer I (0.15 M NaCl, 50 mM Tris-HCl, pH=7.4) for 24 h at 4◦C in 
the presence of protease inhibitors. Protein extracts were then clarified by centrifugation and 
separated from the pellet. This step was repeated by resuspending the pellet in extraction 
buffer II, which contained 1 M NaCl, 25 mM EDTA, 50 mM Tris-HCl, pH=7.4. Following 
extraction with 250mM SDS-containing extraction buffer III (8 h at room temperature), 
guanidine hydrochloride-containing extraction buffer IV (4 M GnHCl, 10 mM EDTA, 50 mM 
Tris-HCl, pH=7.4) was applied for 84 h at 4◦C. The same protein extracts of three donors 
17 
 
were pooled in each investigated group (healthy, non-lesional, lesional). The extraction 
procedure was carried out three times and each contained extracted proteins of three donors 
following the pooling of the samples, which were then subjected to downstream proteomic 
analysis. 
3.2.2 Two-dimensional LC-MS/MS analysis 
A total of 35 µg protein from each sample was applied for mass spectrometry analysis. A 
modified filter-aided sample preparation method was used for tryptic digestion of the protein 
extracts
66
. High-pH reversed-phase chromatography was performed on a C18 column 
(Kinetex 5 µm EVO C18 100 A, 2.1 x 100 mm; cat. no. 00D-4622-AN, flow rate: 150 µl/min, 
Phenomenex, California, USA). 48 fractions were collected from 1 to 25 min. (half 
minute/fraction) and 4-4 fractions were combined (1,13,25,37; 2,14,26,38 and so on) to get 12 
final fractions. Each fraction was subjected to nano LC-MS/MS analysis on an Orbitrap Elite 
Hybrid Mass Spectrometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA) 
coupled with a nanoAcquity UPLC system (Waters, Milford, Massachusetts, USA), using a 
gradient elution after trapping the samples onto the trap column. Data-dependent analyses 
were applied; the 20 most intense peaks were selected for ion-trap collision-induced 
dissociation after each survey scan had been measured in the Orbitrap. Proteome Discoverer 
(version 1.3, Thermo Fisher Scientific, Waltham, Massachusetts, USA) was used to generate 
MS/MS peak-list files and our in-cloud ProteinProspector (version 5.16.0, 
http://prospector.ucsf.edu © Copyright (1996-2019) The Regents of the University of 
California) database search engine was used for protein identification against the human 
sequences from the UniProtKB.2015.12.14.random.concat (149781/55820795 entries 
searched) database (European Bioinformatics Institute (EMBL-EBI), Hinxton Cambridge, 
UK). The schematic overview of the applied proteomic strategy is summarised in Figure 1. 
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Figure 1. Schematic illustration of the applied proteomic workflow (TBS: Tris-buffered saline, 
EDTA: ethylenediaminetetraacetic acid, SDS: sodium dodecyl sulfate, GnHCl: guanidine 
hydrochloride, LC-MS/MS: liquid chromatography – tandem mass spectrometry) 
Detailed protocols and applied counting for semiquantitative analysis is described as 
supplementary information: https://www.nature.com/articles/s41598-019-47774-5#Sec18. 
3.3 Immunofluorescent staining for UDP-glucose 6-dehydrogenase (UGDH) 
For immunofluorescence analysis, 5 µm sections of frozen embedded skin biopsies from 
psoriatic patients (non-lesional and lesional skin) and healthy individuals were used. After 
fixation and permeabilisation (Foxp3 staining buffer set, fixation/permeabilisation kit - 
Miltenyi Biotec, Bergisch Gladbach, Germany - used according to the description of the 
manufacturer), the sections were blocked in Tris-buffered saline (TBS) containing 1% bovine 
serum albumin (BSA) and 1% normal goat serum (NGS) for 1 h at room temperature. 
Samples were incubated overnight at 4°C in TBS with 1% NGS and primary antibody against 
UGDH (rabbit polyclonal antibody, ab155005, Abcam, Cambridge, UK), diluted to 1:100. 
Following washing in TBS, AF546 secondary antibody (Goat anti-Rabbit IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, Alexa Fluor 546, A-11035, Invitrogen, Carlsbad, 
California, USA), diluted in TBS containing 1% NGS to 1:500, was applied for 1 h at room 
temperature. 
3.4 Bioinformatic analysis 
To identify proteins not yet linked with the pathomechanism of psoriasis, literature mining 
was carried out using protein names or the encoding gene’s symbol(s), applying the following 
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strategy: each protein or gene name was searched together with "psoriasis" as a keyword 
using the RISmed R package. 
For the identification of cellular mechanisms that may be associated with the proteins that 
were detected in altered amounts in the proteomic approach, we used the Ingenuity Pathway 
Analysis software (IPA, Qiagen, Redwood City, California, USA). 
3.5 Cell culture and preparation of the cell-treating media 
HaCaT cells kindly provided by Dr. N. E. Fusenig (Heidelberg, Germany) were cultured in 
Dulbecco’s modified Eagle’s medium containing 4.5 g/L glucose, 1.8 mM Ca2+ (DMEM-HG) 
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, 
100 µg/mL streptomycin, 0.25 µg/mL amphotericin B, and grown at 37°C in a humidified 
atmosphere containing 5% CO2. Three to four days after plating, cells were collected from 
semi-confluent cultures by 5-10 min. trypsinisation (0.25% trypsin EDTA solution). The 
proteolic digestion was stopped by FBS and the cells were sedimented (10 min., 4°C, 1500 g) 
and resuspended in the medium for further use. Cellular viability was determined by the 
trypan blue exclusion test. The experiments were performed on cultures, where trypan blue 
was excluded from 95% of the cells. 
For osmolarity measurement, Model 5600 Vapro® Vapor Pressure Osmometer (Dieren, 
The Netherlands) was used. The basal osmolarity of the serum-free DMEM-HG medium was 
338 mOsm. The media contained 3 or 30 mM polyols, respectively, which was equivalent to 
0.027 or 0.27 w/w% glycerol and 0.045 or 0.45 w/w% xylitol
63
. The osmolarity of these 
solutions was also measured. The final osmolarity of 450, 500 and 600 mOsm was reached by 
the addition of the appropriate amount of 1.83 M sorbitol stock solution. Serum-free DMEM-
HG media containing only glycerol, xylitol or sorbitol in concentrations mentioned above, 
respectively, were also applied. 
3.6 Measurement of cellular viability and cytotoxicity 
Cells were seeded into 96-well culture plates at a density of 10
4
 cells/well in DMEM-HG 
supplemented with the appropriate agents detailed above, and serum-starved 24 h before any 
treatments. For 60 min., cells were incubated with or without 0.27% glycerol or 0.45% xylitol 
in serum-free DMEM-HG, followed by incubation with 450, 500 or 600 mOsm, sorbitol-
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containing culture medium with or without 0.27% glycerol or 0.45% xylitol for 24 h. 
Experiments were carried out in triplicates, data are presented as the means of three 
experiments. 
For the cell viability assay, 0.5% MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) solution was added to the cells at 37
o
C for 4 h, then the 
produced formazan crystals were solubilised and the optical density (OD) was measured at 
540 nm by a Multiskan EX spectrophotometer (Thermo Labsystems, Beverly, Massachusetts, 
USA) and Ascent Software (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The 
absorbance rate was compared to untreated samples and represented as the percentage rate of 
living cells. 
Cytotoxicity was assessed by using the Cytotoxicity Detection Kit PLUS (Roche 
Diagnostics, Risch, Switzerland) according to the manufacturer’s instructions. Briefly, 
released lactate dehydrogenase (LDH) was quantified from the supernatant by a colorimetric 
method and OD was measured at 492 nm. Measured values were corrected with the 
background values of the cell-free culture medium. Results are presented in percentage of 
cytotoxicity, where lysed cells correspond to 100% cytotoxicity. 
3.7 Determination of changes in intracellular Ca
2+
 concentration 
HaCaT keratinocytes were plated onto 13 mm diameter uncoated sterile coverslips (VWR, 
Radnor, Pennsylvania, USA) and were left to attach and proliferate for 24 h. Coverslips with 
the attached cells were transferred and incubated in Tyrode’s solution (144 mM NaCl, 0.4 
mM NaH2PO4, 4 mM KCl, 0.53 mM MgSO4, 1.8 mM CaCl2, 5.5 mM glucose and 5 mM 
HEPES, pH=7.4). HaCaT cells were loaded by incubation for 20 min. with the acetoxymethyl 
ester (AM) form of a single wavelength Ca
2+
-sensitive fluorescent dye (Fluo-4, Molecular 
Probes Inc., Eugene, Oregon, USA, 5μM from a stock of 1mM in DMSO + 20% pluronic acid 
Pluronic F-127 Sigma-Aldrich, Saint Louis, Missouri, USA and 6.25 nM/mL Probenecid, 
Molecular Probes Inc., Eugene, Oregon, USA) at room temperature in dark. After the 
incubation period, the cells were washed in indicator-free Tyrode’s solution to remove any 
dye. The technique for intracellular Ca
2+
 detection was based on established procedures 
described earlier
67
. Subsequently, cells were incubated for 30 min. with 0.027 or 0.27% 
glycerol and 0.045 or 0.45% xylitol
63
 in Tyrode’s solution, respectively. 
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Optical measurements were performed using a Zeiss Axiovert 100 microscope (Zeiss, 
Oberkochen, Germany) equipped with a xenon lamp and used in epifluorescent mode at 100x 
magnitude. The coverslips were placed into a low-volume imaging chamber (Warner 
Instruments, Hamden, Connecticut, USA) (37°C) at the microscope stage and cells were 
superfused with Tyrode alone for at least 10 min. (control period). Hyperosmotic stimulus 
was added to the cells in rapid perfusion (2-3 µL/sec) of 450 mOsm, sorbitol-containing 
solution followed by the addition of 30 nmol/mL A23187 ionophor (Sigma-Aldrich, Saint 
Louis, Missouri, USA) in Tyrode. Cells in the 75x75 µm frame were illuminated at 485 nm 
and the emitted light was recorded at 535 nm. Images of relative fluorescence intensity of a 
cell group (3-5 cell/group) were collected in 8-10 independent experiments per treatment 
group with the Mintron 7266pd Color CCD Camera (New Taipei City, Taiwan). Raw data 
were analysed with WinWCP V4.5.0 (Glasgow, Scotland) and Clampfit 10.6 (San Jose, 
California, USA) softwares. 
Calibration was performed by the [Ca
2+
]i = Kd (F-Fmin)/(Fmax-F) method
68
 where [Ca
2+
]i 
is the intracellular Ca
2+
 concentration, Kd is the dissociation constant (345 nM), F is the 
fluorescence intensity evoked with the hyperosmotic stimulus, Fmin values were developed 
from corrected fluorescence intensity before osmotic stress and Fmax values were derived 
from the maximal fluorescence response after the addition of the ionophor solution. 
Background correction was calculated with the autofluorescence of unloaded cells and the 
decrease of fluorescence intensity in untreated cells caused by bleaching or dye efflux. For 
representative figures, ΔCa2+ = ΔF/F = (F − Frest)/Frest) was calculated68. 
3.8 RNA extraction and real-time quantitative reverse transcription polymerase chain 
reaction (RT qRT-PCR) 
Cells were seeded into 6-well plates at a density of 2x10
5
 cells/mL and serum-starved 
overnight. Cells were pre-incubated for 60 min. with 0.27% glycerol or 0.45% xylitol, 
followed by incubation with 450 mOsm, sorbitol-containing medium for 2 and 6 h
46–48
. 
Untreated or only sorbitol-treated cells served as negative or positive controls, respectively. 
Total RNA was isolated using TRIzol reagent (Sigma-Aldrich, Saint Louis, Missouri, USA) 
according to the manufacturer’s instructions. To avoid DNA contamination, DNAse treatment 
was performed and intron-spanning assays were used. cDNA was synthesised from 1 µg total 
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RNA using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, California, 
USA). RT qRT-PCR experiments were carried out with the Universal Probe Library system 
(Roche Diagnostics, Risch, Switzerland) using TaqMan probe-based assays and a C1000 
Touch Thermal Cycler (Bio-Rad Laboratories, Hercules, California, USA). The expression of 
each gene was normalised to the 18S rRNA gene and relative mRNA levels were calculated 
by the ΔΔCt method, compared to untreated, time-matched control samples. 
3.9 Statistical analysis 
3.9.1 Statistical analysis of the proteomic study 
To compare protein abundance from healthy, lesional and non-lesional skin extracts, 
significant differences were determined based on relative peptide ion chromatograms and 
spectrum counting, and evaluated using two different approaches: 1) modified t-test (limma) 
and 2) rank product test (as described by Schwämmle et al.69 following a t-test. We considered 
a protein amount to be different between two samples if at least one test was significant 
(p<0.05) and the absolute fold change was at least two or higher. 
3.9.2 Statistical analysis of the in vitro experiments 
Data analysis was performed with SigmaStat for Windows 11.0 software (Jandel 
Scientific, San Rafael, California, USA). Differences among groups were analysed with one-
way ANOVA and Holm-Sidak post-hoc test and data are presented as mean (m) values with 
standard deviation (SD). When the normality test failed, Kruskal–Wallis one-way analysis of 
variance on ranks, followed by Dunn’s method for pairwise multiple comparison was 
performed. In such cases, median values (M) with 25th and 75th percentiles (25p and 75p, 
respectively) are given. P<0.05 was considered statistically significant.
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4. RESULTS 
4.1 Proteomic results 
4.1.1 Comparison of healthy and lesional skin, and the associated biological processes 
As an initial step, the proteomic results of lesional and healthy skin samples were 
compared and the relative abundance of 249 proteins was found to be different (Figure 2a). A 
protein–protein interaction-based enrichment analysis was performed with these proteins. We 
screened for interaction networks and biological processes related to the observed differences 
in expression using Gene Ontology (GO) analysis of the STRING database (version 10.5). 
Based on the GO nomenclature and protein composition, the identified biological processes 
could be classified into the following categories: development, proliferation, regulation of 
expression and response to stimulus. The ten most significantly different biological processes 
of each category are listed in Figures 2b and 2c. 
a) 
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b) 
 
c) 
 
Figure 2. Characterisation of altered protein expression of lesional (L) skin compared to healthy 
(H) skin. (a) Heatmap of relative expression of proteins differentially expressed in L and H skin 
(left column), and their expression in non-lesional (NL) and H skin (middle column) and NL and 
L skin (right column). (*Significant difference in relative protein expression at least by two-fold in L 
and H comparison.) (b), (c) Biological processes for which proteins were differentially expressed 
in L and H. The top ten processes are depicted for proliferation (b, left, green circles) and 
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development (b, right, blue circles), expression (c, left, filled red circles) and response to stimulus (c, 
right, orange circles). False detection rate (FDR) values are indicated with unfilled red circles around 
the filled circles for the various biological processes. The size of each circle is proportional to FDR 
values (unfilled circles) or to the number of proteins (filled circles). 
Since the major characteristics of psoriatic alterations include altered stress and immune 
responses, as well as dysregulation of proliferation and differentiation, we screened among 
proteins expressed differentially in lesion compared to healthy skin for central regulators 
participating in all four of these mechanisms (Figure 3a). As a result, four central proteins — 
MYBBP1A, PML, PRKDC and STAT1 — were identified, however, only STAT1 had 
previously been associated with psoriasis (PML had been related to psoriasis as ”progressive 
multifocal leukoencephalopathy” not as “promyelocytic leukemia protein”) (Figure 3b). 
a) 
 
b) 
 
Figure 3. (a) Four proteins differentially expressed in healthy and lesional skin are believed to 
participate in all four mechanisms of stress, immune response, proliferation and differentiation, 
(b) however, only STAT1 has already been associated with psoriasis. 
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To determine which lesional alterations and to what extent are manifest in non-lesional 
skin, we selected the 249 proteins that exhibited differential expression in healthy and lesional 
skin, and their expression level was compared to those in non-lesional skin. In non-lesional 
skin, the expression of 79.9% (199) of the 249 proteins differed from the expression in 
healthy and lesional skin by less than two-fold. Therefore, this category was termed as 
intermediate, as they may represent a discrete step in the healthy-to-lesional transition. 
4.1.2 Differential protein expression in non-lesional and lesional skin, and the biological 
processes associated with these proteins 
Comparison of non-lesional and lesional skin proteomes led to the identification of 60 
proteins exhibiting at least two-fold differences in relative abundances. Of these proteins, 34 
exhibited lower protein abundance in non-lesional skin compared to lesions, whereas 26 
exhibited higher abundance (Figure 4a). Functional enrichment analysis of these 60 proteins 
revealed several biological processes identified in psoriasis pathomechanism, including 
development and response to stimulus (Figure 4b). We also found a subset of proteins to be 
differentially expressed in non-lesional and lesional skin, that were not differentially 
expressed in healthy skin and lesions (Figure 4c).
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a) 
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b) 
 
c) 
 
Figure 4. Differential protein expression in lesional (L) and non-lesional (NL) skin, and affected 
biological processes. (a) Heatmap of relative expression for proteins differentially expressed in L 
and NL skin (left column) and the relative expression of these proteins in NL and healthy (H) 
skin (middle column) and L and H skin (right column). (*Significant difference in relative protein 
expression at least by two-fold in L and NL comparison.) (b) Biological processes for which proteins 
were differentially expressed in L and NL are listed. The top ten processes depicted to be affected 
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in response to stimulus (left, filled orange circles) and development (right, filled blue circles). False 
detection rate (FDR) values are indicated with unfilled red circles around the filled circles for the 
various biological processes. The size of each circle is proportional to FDR values (unfilled red 
circles) or to the number of proteins (filled circles). (c) Proteins differentially expressed in L and 
NL but not in H and L skin are listed. (*Significant difference in relative protein expression at least 
by two-fold in L and NL comparison.) 
The levels of 8 proteins were greater in non-lesional skin and lower in lesional skin 
compared to the levels in healthy skin (non-lesional>healthy>lesional), and 1 protein 
exhibited the opposite trend (non-lesional<healthy<lesional). Although the non-lesional and 
lesional differences in the abundance of these proteins were mostly not statistically significant 
when compared to healthy skin, the difference in abundance between non-lesional and 
lesional samples differed significantly by more than two-fold (Table 2). 
 
Table 2. Proteins for which the changes in non-lesional (NL) and lesional (L) skin compared to 
healthy (H) skin are in different directions (increased vs. decreased and vice versa) (*Significant 
difference in relative protein expression at least by two-fold in L and NL comparison. ¥: indicates 
proteins with known association with psoriasis.) 
4.1.3 Comparison of protein expression in non-lesional and healthy skin 
Proteins that were differentially expressed in non-lesional skin compared to healthy were 
also identified. 7 proteins exhibited higher expression levels in non-lesional skin compared to 
healthy skin and 1 showed lower expression (Table 3). Out of the 8 proteins GBP1, KLK10 
and S100A7 have already been associated with psoriasis pathogenesis, while the other 5 are 
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potential novel, early markers of the disease. The relative amount of 4 proteins (GART, 
CSE1L, GBP1 and UGDH) was similar in the non-lesional and lesional skin samples. 
 
Table 3. Differentially expressed proteins in non-lesional (NL) and healthy (H) skin. Proteins with 
expression that differs at least by two-fold in NL skin and H skin are listed. (*: indicates statistical 
significance, ¥: indicates proteins with known association with psoriasis, L: lesional skin.) 
4.1.3.1 Verification of the proteomic results: UGDH expression in healthy, non-lesional 
and lesional skin 
To verify our proteomic results, immunofluorescent staining was performed to gain 
additional information regarding protein localisation, deposition and distribution. UGDH had 
the largest expression differences in non-lesional and healthy skin. As UGDH had not been 
linked to psoriasis previously, this protein was chosen for further analysis. UGDH staining 
showed similar epidermal distribution in all three sample types, with the highest protein levels 
detected in basal keratinocytes (n=10 different individuals in each group). Despite the 
similarities in the UGDH localisation pattern, clear differences in staining intensities were 
observed. The non-lesional and lesional psoriatic samples displayed more robust intensities 
compared to that of healthy samples, confirming our proteomic results (Figure 6). 
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Figure 6. UGDH protein expression is similarly increased in non-lesional (NL) and lesional (L) 
psoriatic skin compared to healthy (H) controls. The highest difference in expression for NL and H 
was seen with immunohistochemical characterisation of UGDH (n=10), which indicated similar 
patterns of distribution in the three sample types. The strongest staining was observed in basal 
keratinocytes, and weaker staining was observed in the upper parts of the epidermis. Higher intensity 
staining of UGDH was observed in NL and L skin compared to H skin A higher magnification of the 
epidermis is also provided (DAPI nuclear staining and UGDH are shown in blue and red, 
respectively.) 
4.1.4 Known and novel psoriasis-associated trigger proteins 
We also identified 44 proteins that had altered expression only in the comparison of 
lesional skin to either non-lesional or healthy skin. It is anticipated that these proteins play a 
role in the manifestation and/or maintenance of lesions. The results of a computer-aided, 
keyword-based literature search suggests that, of these 44 proteins, 23 are already associated 
with the disease (Figure 5a), whereas 21 have not yet been associated with psoriasis 
pathogenesis (Figure 5b). 
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Figure 5. Proteins that exhibited altered expression only in lesions (potentially trigger proteins) 
with known (a) and novel (b) association with psoriasis 
Proteins without previous association to psoriasis that exhibited decreased expression in 
lesions compared to expression in both non-lesional and healthy skin include modulators of 
apoptosis, signaling, endothelial cell proliferation, neurite outgrowth, migration, resistance to 
mechanical stress, cell–cell and extracellular matrix interactions, myelination of peripheral 
nerves, osmotic and membrane potential regulation. In contrast, proteins with increased 
expression in lesions compared to both non-lesional and healthy skin are involved in cell 
death, cell proliferation, transcription and translation, Ca
2+
 sensing (neuronal) and processing 
of class I MHC peptides. 
4.1.5 Psoriatic biomarkers, biological functions, canonical pathways and annotation of 
diseases associated with the detected alterations in protein amounts 
To examine the validity of our experimental approach, we further screened our proteomic 
dataset (lesional vs. healthy) for known, major biomarkers characteristic of psoriasis. These 
were identified previously in large-scale genomic, transcriptomic and/or proteomic studies. 
Out of these biomarkers AKR1B10, CSTA, FABP5, PI3, SCCA2, STAT1, STAT3 and 
members of the S100 family, including S100A2 and S100A7-9 were also found in our study. 
These molecules exhibited elevated expression levels in psoriatic lesions, compared to healthy 
control skin (Table 4). 
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Table 4. Detected expressional differences of classic protein biomarkers for psoriasis (*: indicates 
statistical significance, L: lesional, NL: non-lesional psoriatic skin, H: healthy skin). 
Further analysis was performed to identify the cellular mechanisms that may be associated 
with the proteins that were detected in altered amounts in the proteomic approach, using the 
IPA software. Diseases annotation revealed “psoriasis” as the first hit when lesional and 
healthy, or lesional and non-lesional differences were compared. Annotation of biological 
functions by IPA highlighted “initiation of protein translation” and “killing of Staphylococcus 
aureus” as the main functions likely to be affected, respectively. Ingenuity canonical pathway 
screening identified the “role of IL-17A in psoriasis” among the top ten most significant 
canonical pathways, when either lesional or non-lesional protein expression was compared to 
healthy samples. In addition, several cancer, neurological, neuromuscular canonical pathways 
were also highlighted. 
Detailed proteomic results are found in the main article 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684579/) and in the supplementary 
material (https://www.nature.com/articles/s41598-019-47774-5#Sec18). 
4.2 In vitro results 
4.2.1 Effects of glycerol and xylitol on the viability of HaCaT cells exposed to 
hyperosmotic stress 
During a period of 24 h, osmotic stresses of 450 and 500 mOsm did not influence cellular 
viability, and the average cytotoxicity values were negligible. However, 600 mOsm, sorbitol-
containing solution significantly reduced viability. The reduction was also considerable in the 
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additional polyol-treated groups, but glycerol treatment resulted in significantly higher 
viability as compared to the positive control (DMEM-HG + sorbitol (600 mOsm)) group. 
0.45% xylitol failed to improve the survival of the cells. The average cytotoxicity value of the 
0.27% glycerol + sorbitol (600 mOsm)-treated group was somewhat lower than that of its 
control group (DMEM-HG + sorbitol (600 mOsm)), but the difference was not significant. 
Viability and cytotoxicity in groups exposed to 0.27% glycerol and 0.45% xylitol alone did 
not differ significantly from that of their matched DMEM-HG control group (Figure 7). 
 
Figure 7. (a) The effects of glycerol and xylitol on cellular viability in hyperosmotic stress. (b) 
The effects of polyols in osmotic stress-induced cytotoxicity. (DMEM-HG: Dulbecco’s modified 
Eagle’s medium containing 4.5 g/L glucose, sor: sorbitol, gly: glycerol, xyl: xylitol.) Statistical 
analysis was performed with one-way ANOVA and Holm-Sidak post-hoc test (mean+SD), *p<0.05 
vs. DMEM-HG., #p<0.05 vs. DMEM-HG + sor (600 mOsm), n=3. 
4.2.2 0.45% xylitol protected against the hyperosmotic stimulus-induced increase in 
intracellular Ca
2+
 concentration 
Hyperosmotic stress induced by 450 mOsm, sorbitol-containing solution was accompanied 
by a short elevation of intracellular Ca
2+
 concentration. This elevation (M=328.6 nM, 
25p=232.0, 75p=602.4) was prevented neither by glycerol nor the lower concentration of 
xylitol, but it was suppressed by the higher concentration (0.45%) of xylitol (M=78.76 nM, 
25p=45.92, 75p=140.72) (Figure 8a). Figure 8 also shows two representative curves of this 
response from the sorbitol-treated (Figure 8b) and the sorbitol and 0.45% xylitol-treated 
groups (Figure 8c). 
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Figure 8. (a) Xylitol protected against the hyperosmotic stimulus-induced increase in 
intracellular Ca
2+
 concentration. (Sor: sorbitol, gly: glycerol, xyl: xylitol.) Statistical analysis was 
performed with Kruskal–Wallis one-way analysis of variance on ranks, followed by Dunn’s method 
(median, 25th and 75th percentile), *p<0.05 vs. sor, n=8-10. (b-c) A representative curve of the 
relative fluorescence on sorbitol (450 mOsm) (b) and additional xylitol-treated group (c) 
4.2.3 Preventive effects of polyols on the elevation in the mRNA expression of 
inflammatory cytokines and NFAT5 induced by osmotic stress 
The mRNA expression of inflammatory cytokines (TNF-α, IL-1α, IL-1β, IL-6 and IL-8) 
and the osmosis-related NFAT5 was measured after 2 and 6 h hyperosmotic stress. After 6 h, 
no significant changes were detected (data not presented). Following 2 h treatment, the 
cytokine levels of glycerol- or xylitol-treated groups were similar to that of the untreated 
control group. 450 mOsm, sorbitol-containing medium induced considerable increase in IL-
1α, IL-1β, IL-8 and NFAT5 expression. Both 0.27% glycerol and 0.45% xylitol prevented the 
elevation in the expression of IL-1α (Figure 9a). Furthermore, both 0.27% glycerol and 
0.45% xylitol led to considerably lower expression of IL-8 in osmotic stress; the expression 
levels did not differ significantly from those of the untreated control group (Figure 9d). As 
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concerns IL-1β and NFAT5, only 0.27% glycerol diminished considerably their expression 
(Figure 9b, c). No significant difference was found among the six study groups in TNF-α and 
IL-6 expression (data not shown). 
 
Figure 9. In vitro effects of polyols on (a) IL-1α, (b) IL-1β, (c) NFAT5 and (d) IL-8 expression 
(Sor: sorbitol, gly: glycerol, xyl: xylitol.) The expression of each gene was normalised to the 18S 
rRNA gene and relative mRNA levels were calculated by the ΔΔCt method, compared to the 
untreated, time-matched control samples. Statistical analysis was performed with one-way ANOVA 
and Holm-Sidak post-hoc test (mean+SD), *p<0.05 vs. Contr., #p<0.05 vs. sor (450 mOsm), n=3 (a-c) 
and Kruskal–Wallis one-way analysis of variance on ranks, followed by Dunn’s method (median, 25th 
and 75th percentile), *p<0.05 vs. Contr., n=3 (d). Despite the difference in the statistical tests, 
mean+SD values are shown in all subfigures for uniform presentation.
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5. DISCUSSION 
To expand knowledge about the pathomechanism of psoriasis, many extensive, large-scale 
comparative proteomic approaches have been performed
11,20,26
. However, the comparison of 
healthy, non-lesional and lesional skin at the proteomic level has been missing from these 
studies. To fill this gap, our proteomic analysis included healthy skin as well as non-lesional 
and lesional psoriatic samples. 
In order to check the validity of our proteomic approach, we compared major known 
psoriatic biomarkers published in previous genetic (genome-wide association studies)
15
, 
transcriptomic
13,15,18
 and proteomic studies
11,12,14,17
 with our proteomic dataset. Known 
psoriatic lesional biomarkers also found in our study include AKR1B10
10
, CSTA
11
, FABP5
12
, 
PI3
13
, SCCA2
14
, STAT1
10
, STAT3
15
, S100A2
16
, S100A7
12–14
, S100A8
13,17
 and 
S100A9
13,14,17,18
. Moreover, annotation of diseases resulted in the identification of psoriasis 
with the strongest correlation based on differentially expressed proteins in either lesional vs. 
healthy or in lesional vs. non-lesional comparison. Canonical pathway analysis of either 
lesional or non-lesional differences compared to healthy skin resulted in the identification of 
the “role of IL-17A in psoriasis”. However, these annotations also highlighted cancer, 
neurological, neuromuscular or muscular disease-related mechanisms, suggesting their 
potential involvement in disease pathomechanism, or some similarities between these 
diseases. 
Since our proteomic and in silico analysis cannot distinguish between cell types and 
provide information whether mechanistically linked alterations  take place within the same or 
different cell types, further experiments are required to clarify the exact relevance of these 
predicted connections to psoriasis pathomechanism. 
We performed a literature search for known functions of proteins found to be altered in 
amounts in our study to suggest mechanisms through which they may potentially participate 
in the pathomechanism of the disease. The detected differences in the expression of proteins 
in healthy and lesional skin highlighted the involvement of cell proliferation
70
, development
71
, 
response to stimulus
72
 and expression
73
-related processes in psoriasis. Comparing non-
lesional and lesional skin, we identified 60 proteins with differential expression, which 
represent only 24.1% of the number of proteins, which showed altered expression in the 
comparison of healthy and lesional skin (60 vs. 249). This highlights the importance of 
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studying healthy skin in comparisons using patient samples for pinpointing disease-associated 
alterations. Qualitative literature-based analysis of these 60 proteins led to the identification 
of several mechanisms, the association of which with psoriasis has already been described, 
including processes related to development
71
, response to stimulus
26
 and expression
73
. 
We searched for potential central proteins in disease pathogenesis participating in key 
mechanisms of psoriasis including regulation of stress and immune response, proliferation 
and differentiation. Out of the central proteins, STAT1 had already been linked to psoriasis
74
, 
however, we also identified 3 proteins, MYBBP1A, PML and PRKDC, which had not 
previously been highlighted in context with the disease. The suggested altered expression by 
our results of the transcription factor MYBBP1A may also be among the potentially important 
proteins implicated in the pathogenesis of psoriasis since it functions as a co-repressor of NF-
κB that may regulate responses to stress and cytokines75. An isoform of PML (PML-4) is 
known to regulate apoptosis and growth suppression, while the nuclear isoforms are involved 
in gene expression regulation at the MHC-I locus
76
. The PRKDC may play a role in the 
detection and repair of breaks in double-stranded DNA
77
 and mediates the phosphorylation of 
c-Myc
78
 and p53
79
 suggesting a potentially important role in psoriasis. 
Proteins whose expression was affected only in lesions are often considered “trigger” 
proteins, as changes in the expression of these proteins are linked to the shift of the disease 
state. The proteins that had not previously been associated with psoriasis were categorised 
into two groups. The first group of proteins might contribute to the mechanosensitivity of the 
tissue (SGCD
80
, SYNM
81
, MYH11
82
, ATP1B1
83
). The second group functions within the 
nervous system (MPZ, PRX
84
, CSPG4
85
, CNTN1 and ITGA8
86
, ATP1B1
87
), which could 
suggest the involvement of the peripheral nervous system in psoriasis
88
. 
By comparing non-lesional and healthy skin, differential expression was observed for 8 
proteins (CSE1L, GART, GBP1, KLK10, MYO18A, S1007A, SMARCA5 and UGDH). 4 of 
these proteins (CSE1L, GART, GBP1 and UGDH) might be predisposing factors, as their 
expression was similar in non-lesional and lesional skin, and their significance would have 
been missed in comparisons in which healthy samples were not included. Of these 4 proteins, 
UGDH was detected with the highest relative difference. UGDH had not been highlighted 
previously in association with psoriasis. We therefore decided to analyze it further. An 
immunohistochemical analysis confirmed our proteomic results: higher UGDH levels were 
40 
 
found in non-lesional and lesional skin compared to healthy skin, that was mainly associated 
with keratinocytes. Elevated UGDH levels may increase chondrocyte proliferation indirectly, 
probably through increased hyaluronan production that binds different cytokines
89
. However, 
in vitro downregulation of UGDH and consequently decreased hyaluronan amounts did not 
influence keratinocyte proliferation
90
. These results are in line with our observation, 
suggesting that elevated UGDH levels observed in non-lesional keratinocytes are not 
sufficient to modify their proliferation. 
A further analysis focused on gaining insight about the extent to which alterations are 
manifest in lesions and in non-lesional skin. Strikingly, nearly 80% of the 249 proteins 
exhibiting differential expression in lesional and healthy skin exhibited an intermediate 
expression level in the non-lesional skin, suggesting the possible presence of early, lesional-
like alterations in the non-lesional skin. Divergence from this trend was only observed in two 
small protein groups. 10 proteins — CHCHD6, CHMP5, COLEC12, FLOT2, ITGA7, 
LEMD2, NOP56, PLVAP, RRAS and SMARCA5 — differed in relative protein amounts in 
non-lesional and lesional skin, but the amounts of these proteins were similar in healthy and 
lesional samples. These 10 proteins are likely to represent a group of non-lesional 
characteristic alterations. For 9 proteins — CD207, COLEC12, CTSV, ITGA7, ITGA8, 
PLVAP, PSAPL1, SMARCA5 and XP32 — the direction of the expressional changes was 
different in non-lesional and lesional samples compared to healthy skin. It might represent 
proteins that contribute to maintaining the non-lesional state. 
Next, with the proteins in these two groups, we performed an extensive literature search to 
suggest potential mechanisms by which they may influence disease pathogenesis. 
Interestingly, all the identified proteins may play a role in signaling at different levels starting 
from the cell surface all the way to the nucleus or mitochondria. The identified cell surface 
receptors include two integrins (ITGA7 and ITGA8) that are important in external signal 
recognition. Decreased ITGA7 levels — as observed in lesional vs. non-lesional skin — 
might be associated with delayed autophagy
91
, differentiation
92
 and increased migration
93
, all 
known to be affected in psoriatic lesions. In contrast, elevation of ITGA7 may induce growth 
suppression
94
. However, ITGA7 is characteristically expressed mainly by smooth muscle 
cells
95
 in the skin, suggesting that its involvement in keratinocyte-related events is limited or 
none. Instead, it may suggest alterations in (vascular) smooth muscle cell adhesion-related 
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processes
96
. Alternatively, ITGA7 may influence neurite outgrowth
97
. Therefore, further 
studies are required to confirm the observed ITGA7 expression alteration and to identify the 
cell types of source. 
FLOT2
98
, CHMP5
99 and COLEC12
100
 participate in endocytic pathways, regulating the 
levels of cell surface receptors and, thereby, signaling. FLOT2 is a known component of the 
raft microdomain complex that represents the major unit regulating STAT signaling pathways 
according to the raft-STAT signaling hypothesis
101
. The alteration of FLOT2 expression could 
suggest a high relevance since STAT3 is a key regulator in psoriasis
102
. Reduction of the 
scavenger receptor COLEC12 could trigger psoriasis by trastuzumab treatment
103
. Moreover, 
COLEC12 may influence the mitochondrial respiratory chain
104
, and this property is in 
agreement with the decreased level of the mitochondrial MICOS complex subunit 
CHCHD6
105
 observed in lesions compared to non-lesional skin. CHCHD6 regulates oxygen 
consumption and thereby may influence cell growth
106
. Reduced levels of CHCHD6 were 
shown previously to lead to a shift from oxidative metabolism to glycolytic metabolism
107
 
that influences keratinocyte differentiation
108
 negatively, and both types of mechanisms are 
known to be affected in psoriasis
109,110
. 
The altered expression of LEMD2 may suggest that signal transduction is also altered at 
the level of the nucleus. LEMD2, located in the inner nuclear membrane, regulates nuclear 
import/export processes
111
 and thereby intranuclear signaling
106
. During this regulation, 
LEMD2 is associated with the same complex as CHMP5, which was also identified in our 
studies. In the nucleus, the STAT-regulated protein NOP56
112
, a core protein of the box C/D 
small nucleolar ribonucleoprotein (snoRNP) complex, participates in the biogenesis of 
rRNAs
113
. Increased rRNA biogenesis is suggested to be necessary for high proliferation 
rate
114
, a process that is crucial for the development of psoriatic lesions. 
Overall, our results indicate that dysregulation of cellular signaling — from signal 
detection through endocytosis of receptors and transduction of signal from the cell surface to 
the nucleus — may be affected during the disease. The alteration of these systems is likely to 
lead to increased reaction to external signals that could contribute to the maintenance of 
psoriatic plaques. 
During psoriatic plaque formation, abnormal proliferation
70
, differentiation
108
 and thereby, 
skin barrier function are key processes. Among proteins identified with altered amount in the 
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proteomic analysis, SMARCA5 is a component of the nucleosome remodelling factor 
complex
115
. Decreasing SMARCA5 levels are required for basal keratinocytes to shift from 
proliferation toward differentiation
116
. XP32 is also a component of the epidermal 
differentiation complex
117
 and it is associated with skin barrier function
118
. Further proteins 
related to mechanical stress (for example SYNM
81
) and disturbances of osmoregulation (such 
as ATP1B1
83
) were also identified. These alterations with the abnormal barrier function are 
characteristic not only of psoriasis, but also of irritant contact dermatitis (ICD). 
ICD is a frequent occupational disorder
119
, which is characterised by impaired barrier 
function leading to increased TEWL. Water evaporation exposes keratinocytes to a condition 
of high osmotic pressure
52
. In our previous animal experiments, sodium lauryl sulfate (SLS)-
induced skin irritation resulted in the reduction of epidermal thickness
61
 that can be 
considered as an indirect evidence for osmotic stress. Therefore, the present study was aimed 
at the investigation of osmotic challenge potentially accompanying ICD. In response to 
hyperosmotic stress, organic osmolytes are accumulated by the cells. In the skin, betaine, 
myoinositol and taurine are important osmolytes and the expression of their transporters 
(betaine/GABA transporter, sodium/myoinositol transporter and taurine transporter) is 
induced by osmotic stress
120
. 
The anti-irritant and anti-inflammatory effects of glycerol and xylitol have already been 
demonstrated in animal experiments
61
. Joint application of glycerol and xylitol increases skin 
hydration, decreases TEWL, improves biomechanical properties of the skin and induces a 
higher filaggrin production in the epidermis after 2 weeks of application
62
. However, their 
cellular mechanism of action has not been revealed in details. We assumed that these polyols 
may act as organic osmolytes, this way they may have a role in osmoregulation. 
Effects of polyols may depend on the applied concentration
61,121
. Hence, two different 
concentrations were tested in our in vivo studies
60,61
 and also two different concentrations 
were chosen for the present experiments, based on previous in vitro results
63
. According to the 
results of the effect of polyols on Ca
2+
 concentration in our preliminary experiments, only the 
higher polyol concentrations were applied in the measurement of cellular viability, 
cytotoxicity and cytokine expression. 
In order to induce osmotic stress, instead of the ionic sodium chloride and the detergent 
SLS, sorbitol was chosen, which is a metabolically inactive, inert agent. Sorbitol is also a 
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polyol osmolyte such as glycerol and xylitol, however, it has no known protective effect in 
inflammatory skin conditions, and it is used to induce osmotic stress
51
. 
Osmotic challenge influences cellular viability in an osmolarity- and time-dependent 
manner
47–50
. Such an effect is also characteristic of ICD: severe irritation of the skin (24 h 
exposure to SLS) can induce tissue necrosis in vivo
122
 but milder irritant challenges do not 
lead to necrosis
123
. In our experiments, 24 h exposure to 450 and 500 mOsm, sorbitol-
containing medium did not influence cellular viability and cytotoxicity, but 600 mOsm 
resulted in a significant decrease in viability as compared to untreated control cells. 
However, instead of 600 mOsm, 450 mOsm osmotic stress was applied to measure 
intracellular Ca
2+
concentration, in order to examine the protective effects of polyols, with the 
elimination of cell death. According to our pilot study, 450 mOsm, sorbitol-containing 
hyperosmotic stimulus was sufficient to induce a short elevation of intracellular Ca
2+
 with 
kinetics similar to that measured by Dascalu et al. who applied 500 mOsm, sucrose-
containing solution
49
. Although the exact molecular mechanism is still not fully clarified, 
dihydropiridine-sensitive Ca
2+ 
channels have been described not to be affected
49
. The transient 
receptor potential vanilloid 1b (TRPV1b) non-selective cation channel, which is expressed 
also by HaCaT cells
124
, can be induced by cell shrinking in hypertonicity
125
 and therefore may 
have a potential role in Ca
2+
 response. In osmotic stress, increased inositol 1,4,5-trisphosphate 
(IP3) and diacylglycerol (DAG) synthesis were observed, as well
126
. TRPV1 can also be 
activated by Ca
2+ 127 
and DAG
128
. Moreover, IP3 receptors may contribute to Ca
2+
 influx, 
too
129
. 
Based on literature data
63
, the applied polyols alone did not influence intracellular Ca
2+
 
concentration. Our results show that xylitol prevented the elevation of intracellular Ca
2+ 
concentration induced by the hyperosmotic sorbitol solution, while glycerol did not influence 
this parameter. Further investigations are necessary to reveal the reason for this difference and 
the exact mechanism via which xylitol inhibits Ca
2+
 signal. 
In addition to the rapid Ca
2+ 
response, the applied osmotic challenge has longer effects, as 
well. 2 h of exposure to 450 mOsm, sorbitol-containing medium increased the expression of 
IL-1α, IL-1β and IL-8 in HaCaT cells. Terunuma and colleagues have described that cytokine 
expression elevates in keratinocytes when 500 mOsm of osmotic stimulus is present for 6 h
52
. 
Cytokine production may originate from the Ca
2+
 response
130
. However, in a recent study, 
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pro-inflammatory responses evoked with ATP- or bradykinin-induced elevation of the 
intracellular Ca
2+
 concentration could not be suppressed by glycerol or xylitol. Moreover, 
none of these polyols influenced the subcellular translocation of the Ca
2+
-dependent protein 
kinase C-α (PKC-α). However, xylitol but not glycerol translocated the Ca2+-independent 
PKC-δ131. TRPV1 activation can also lead to enhanced cytokine production via direct or 
indirect NF-κB activation132. Independently from the Ca2+ response, hyperosmotic stress also 
induces the expression of the transcription factor NFAT5
48
, which regulates TNF-α133 and can 
bind the promoter of IL-1 and IL-6
57
. Thus, elevated expression of NFAT5 might have 
contributed to the increased cytokine response in the present study. Our previous in vivo 
investigations have already shown the anti-inflammatory effect of glycerol and xylitol
60–62
. 
However, differences can be found as compared to the present in vitro results. Glycerol and 
xylitol decreased the mRNA expression of IL-1β and TNF-α, but had no effect on the IL-1α 
levels in a murine model of ICD
61
. Several factors may explain the beneficial effects of 
polyols on cytokine expression. In addition to the prevention of Ca
2+
 signal and the inhibition 
of NFAT5 expression, glycerol and xylitol may affect the inflammatory process via 
stabilising protein structure. As chaperon osmolytes, these polyols are able to enhance protein 
folding, thereby assisting in the development of the final structure essential for the optimal 
enzyme function, and they promote protein-protein and protein-DNA interactions
134
. 
Our findings indicate that glycerol provides protection not only against acute inflammation 
but also against a more serious damage, which occurs after a relatively longer time-span. The 
protective effect of glycerol was found to appear after a 24 h exposure to osmotic stress when 
aquaporin-3 (AQP-3) gene expression shows a peak
135
. If AQP-3 expression increases at 
protein level, as well, it provides an enhanced intracellular transport of glycerol. This theory 
is supported by our observation that cellular viability was ameliorated only when glycerol was  
continuously available (data not shown).
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SUMMARY 
In this study, a complex comparison of the psoriatic lesional, non-lesional and healthy skin 
was performed by semi-quantitative proteomic analysis. In addition, the effects of glycerol 
and xylitol were tested under hyperosmotic conditions as an in vitro model of osmotic stress 
accompanying psoriasis, ICD and other xerotic skin diseases. 
 Our comparative proteomic approach of healthy, non-lesional and lesional skin led to 
the identification of various proteins, which may function in psoriasis pathogenesis, providing 
a strong base for future studies. 
 Proteins exhibiting opposite expression changes in lesional and non-lesional samples 
compared to healthy skin may function in the maintenance of the non-lesional stage and may 
represent future targets for therapeutic purposes. 
 Glycerol supported cell viability, while xylitol prevented the hyperosmosis-induced 
Ca
2+
 signal, and both polyol protected against the increased expression of some inflammatory 
cytokines in hyperosmotic stress. 
 Despite the similar chemical structure of glycerol and xylitol, their effects displayed 
some differences. Hence, joint application of glycerol and xylitol may be a useful therapeutic 
approach for different skin disorders. 
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comprehensive proteomic Analysis 
Reveals intermediate Stage of non-
Lesional psoriatic Skin and points 
out the importance of proteins 
outside this trend
edit Szél1, Renáta Bozó1, Éva Hunyadi-Gulyás  2, Máté Manczinger1,3, Kornélia Szabó1,3, 
Lajos Kemény  1,3, Zsuzsanna Bata-Csörgő1,3 & Gergely Groma1,3
to better understand the pathomechanism of psoriasis, a comparative proteomic analysis was 
performed with non-lesional and lesional skin from psoriasis patients and skin from healthy individuals. 
Strikingly, 79.9% of the proteins that were differentially expressed in lesional and healthy skin exhibited 
expression levels in non-lesional skin that were within twofold of the levels observed in healthy and 
lesional skin, suggesting that non-lesional skin represents an intermediate stage. proteins outside this 
trend were categorized into three groups: I. proteins in non-lesional skin exhibiting expression similar to 
lesional skin, which might be predisposing factors (i.e., CSE1L, GART, MYO18A and UGDH); II. proteins 
that were differentially expressed in non-lesional and lesional skin but not in healthy and lesional skin, 
which might be non-lesional characteristic alteration (i.e., CHCHD6, CHMP5, FLOT2, ITGA7, LEMD2, 
NOP56, PLVAP and RRAS); and III. proteins with contrasting differential expression in non-lesional and 
lesional skin compared to healthy skin, which might contribute to maintaining the non-lesional state 
(i.e., ITGA7, ITGA8, PLVAP, PSAPL1, SMARCA5 and XP32). Finally, proteins differentially expressed in 
lesions may indicate increased sensitivity to stimuli, peripheral nervous system alterations, furthermore 
MYBBP1A and PRKDC were identified as potential regulators of key pathomechanisms, including stress 
and immune response, proliferation and differentiation.
To date, all therapies available for psoriasis only manage symptoms. Understanding alterations that cause the 
disease is highly important for developing new therapies to better manage the disease.
Our skin connects, and at the same time separates internal the external environment. It is constantly subjected 
to many different stimuli that requires proper response, through which the skin can influences the function of 
other organs, like the brain and the endocrine system in a mutual way1,2. In psoriasis, the macroscopically healthy 
looking non-lesional skin harbors alterations that might cause symptoms3. One of the most characteristic prop-
erties of non-lesional skin is an altered response to mechanical stress or injury4 leading to barrier disruption5, 
which leads to an elevated innate immune response6,7. Alterations in non-lesional skin are not restricted to kerat-
inocytes. Angiogenesis is also among those mechanisms that is already affected in non-lesional skin, resulting 
in altered quantity and quality of microvessels8. In addition, it is becoming clear that some adaptive immune 
responses are also altered9. Abnormalities in the dermal extracellular matrix composition — such as elevated 
expression of the oncofetal splice variant of fibronectin10, due to altered splicing events11 indicate the involve-
ment of dermal fibroblasts3. Several matrix metalloproteinases (MMPs), such as MMP-9, previously thought 
to be increased only in lesions, are now known to be elevated in non-lesional skin compared to healthy skin12. 
There is also evidence for mechanisms in non-lesional skin that contribute to the maintenance of its state. The 
PRINS long non-coding RNA is induced by stress and nucleic acids, and it is anticipated to have a protective 
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function in psoriasis. PRINS in the non-lesional skin not only decreases inflammatory responses13 by inhibit-
ing IL-6 and CCL-5 mRNA translation, but also influences anti-apoptotic mechanisms14. Elevated expression of 
the anti-inflammatory regulator caspase recruitment domain family member 18 (CARD18) in non-lesional skin 
compared to healthy skin was found to aid the inhibition of inflammatory events15. These mechanisms, among 
many others, highlight the relevance of comparing non-lesional skin to healthy skin.
One of the most effective ways to study different diseases with such a high complexity and to elucidate 
related mechanisms is to perform a comparative proteomic analysis of protein extracts derived from affected 
tissues. Previous large-scale treatises including genomic, transcriptomic and proteomic studies have identified 
psoriasis-related markers playing key roles in the pathomechanism, such as AKR1B1016, CSTA17, FABP518, PI319, 
SCCA220, STAT116, STAT321, S100A718–20, S100A819,22 and S100A919,20,22,23, among others, thereby contributing 
greatly to the better understanding of the disease. However, none of the full scale proteomic studies17,18,22,24–27 
to the best of our knowledge, compared lesional and non-lesional psoriatic full thickness skin regions, with the 
inclusion of biopsies from healthy individuals as a reference in the comparison. The inclusion of healthy skin 
could provide several important additional information. I. Alterations that are similar in non-lesional and lesional 
skin, but differ from healthy skin, can be detected and used to identify potential novel disease markers or predis-
posing factors already present in the non-lesional skin. II. The comparison of non-lesional skin to healthy skin 
might facilitate the identification of inherent characteristics of psoriatic patients that are already present in their 
healthy-looking skin prior to lesion development. III. Information could be gained about the extent to which the 
non-lesional skin is affected in respect to lesional alterations. IV. Altered processes in the non-lesional skin that 
are contrary to the changes of lesional skin could be identified, some of which may contribute to the maintenance 
of the non-lesional state and serve as novel intervention points for disease management. We aimed to extend 
previous proteomic studies, in order to get more information regarding the putative alterations mentioned above. 
Therefore, a complex comparison was performed, where in addition to non-lesional and lesional skin, samples 
from healthy skin were also included, in a label-free, semi-quantitative proteomic analysis.
Results
Proteomic workflow and information on involved donors. Three biological replicas of our pro-
teomic approach were performed following sequential protein extraction of total skin biopsies. Each proteomic 
replica contained samples from three healthy donors as well as non-lesional and lesional biopsies from three 
psoriatic patients. The schematic overview of the applied proteomic strategy is summarized in Fig. 1 (also see 
Supplementary Information: Materials and Methods), and basic demographic and clinical characteristics of pso-
riatic patients and healthy donors are listed in Table 1. (Criteria for inclusion of patients in the study and skin 
sample collection are described at Supplementary Material: Materials and Methods section).
Biological processes associated with differential expression in healthy and lesional skin. As an 
initial step, proteomic results of lesional and healthy skin samples were compared and the relative abundance of 
249 proteins was found to be different (Fig. 2a and Supplementary Table 1). A protein–protein interaction-based 
enrichment analysis was performed with these proteins. We screened for interaction networks and biological 
processes related to the observed differences in expression using Gene Ontology (GO) analysis of the STRING 
database (version 10.5). Based on the GO nomenclature and protein composition, the identified biological pro-
cesses could be classified into the following categories: development, proliferation, regulation of expression and 
response to stimulus related processes. The ten most significantly different biological processes of each category 
are listed in Fig. 2b,c and Supplementary Table 2.
Since the major characteristics of psoriatic alterations include altered stress and immune responses as well as 
dysregulation of proliferation and differentiation, we screened among proteins expressed differentially in lesion 
compared to healthy skin for central regulators participating in all four of these mechanisms (Fig. 2d). As a result, 
four central proteins — MYBBP1A, PML, PRKDC and STAT1 — were identified (Fig. 2e).
Differential protein expression in non-lesional and lesional skin and the biological processes 
associated with these proteins. Comparison of non-lesional and lesional skin proteomes led to the iden-
tification of 56 proteins exhibiting at least 2-fold differences in relative abundances. Of these proteins, 32 exhib-
ited higher protein abundance in non-lesional skin compared to lesions, whereas 24 exhibited lower abundance 
(Fig. 3a and Supplementary Table 3). Functional enrichment analysis of these 56 proteins revealed several biolog-
ical processes identified in psoriasis pathomechanism, including development, and response to stimulus (Fig. 3b 
and Supplementary Table 4).
We also found a subset of proteins to be differentially expressed in non-lesional and lesional skin that were not 
differentially expressed in healthy skin and lesions (Fig. 3c).
The levels of eight proteins were greater in non-lesional skin and lower in lesional skin compared to the levels 
in healthy skin (non-lesional < healthy < lesional), and one protein exhibited the opposite trend (non-lesional > 
healthy > lesional). Although the non-lesional and lesional differences in the abundance of these proteins were 
not statistically significant when compared to healthy skin, the difference in abundance between non-lesional and 
lesional samples differed significantly by more than two-fold (Fig. 3d).
We also identified 44 proteins that had altered expression only in the comparison of lesional skin to either 
non-lesional or healthy skin; it is anticipated that these proteins play a role in manifestation and/or maintenance 
of lesions. The results of a computer-aided, keyword-based literature search suggests that, of these 44 proteins, 
23 are already associated with the disease (Fig. 3e), whereas 21 have not yet been associated with psoriasis patho-
genesis (Fig. 3f).
Proteins without previous association to psoriasis that exhibited decreased expression in lesions compared to 
expression in to both non-lesional and healthy skin include modulators of apoptosis, signaling, endothelial cell 
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proliferation, neurite outgrowth, migration, resistance to mechanical stress, cell–cell and extracellular matrix 
interactions, myelination of peripheral nerves, osmotic and membrane-potential regulation (Supplementary 
Table 5). In contrast, proteins with increased expression in lesions compared to both non-lesional and healthy 
skin are involved in cell death, cell proliferation, transcription and translation, calcium sensing (neuronal) and 
processing of class I MHC peptides (Supplementary Table 5). To further elucidate the significance in psoriasis 
of the differential expression of these latter three groups of proteins (Fig. 3c,d,f), a detailed automated literature 
analysis was conducted for associated known functions.
Comparison of protein expression in non-lesional skin compared to healthy skin. Proteins 
that were differentially expressed in non-lesional skin compared to healthy were also identified. Seven proteins 
exhibited higher expression levels in non-lesional skin compared to healthy skin and one with lower expression 
Figure 1. Schematic illustration of the applied proteomic workflow.
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(Fig. 4a). Among these, the relative amount of four proteins (GART, CSE1L, GBP1 and UGDH) was similar in the 
non-lesional and lesional skin samples. Out of the eight proteins that are differentially expressed in non-lesional 
skin compared to healthy GBP1, KLK10 and S100A7 have already been associated with psoriasis pathogenesis; 
the other five are potential novel, early markers of the disease.
To verify our proteomic results, immunofluorescent staining was performed to gain additional information 
regarding protein localization, deposition and distribution. UGDH had the largest expression differences in 
non-lesional and healthy skin. As UGDH has not been linked to psoriasis previously, this protein was chosen for 
further analysis. UGDH staining showed similar epidermal distribution in all three sample types, with the highest 
protein levels detected in basal keratinocytes (n = 10 different individuals in each group, listed in Supplementary 
Table 6). Despite the similarities in the UGDH localization pattern, clear differences in staining intensities were 
observed. The non-lesional and lesional psoriatic samples displayed more robust intensities compared to that of 
healthy samples, confirming our proteomic results (Fig. 4b,c).
To determine which lesional alterations and to what extent are manifest in non-lesional skin, we selected the 
249 proteins that exhibited differential expression in healthy and lesional skin and their expression levels was 
compared to those in non-lesional skin. In non-lesional skin, the expression of 199 (79.9%) of the proteins dif-
fered from the expression in healthy and lesional skin by less than two-fold. Therefore, this category was termed as 
intermediate, as they may represent a discrete step in the healthy-to-lesional transition (Supplementary Table 7).
psoriatic biomarkers, biological functions, canonical pathways and annotation of diseases 
associated with the detected alterations in protein amounts. To examine the validity of our exper-
imental approach, we further screened our proteomic dataset (lesional vs. healthy) for known, major biomarkers 
characteristic for psoriasis. These were identified previously in by large scale genomic, transcriptomic and/or 
proteomic studies. Out of these biomarkers AKR1B10, CSTA, FABP5, PI3, SCCA2, STAT1, STAT3 and members 
of the S100 family, including S100A7, S100A8, S100A9 were also found in our study. These molecules exhibited 
elevated expression levels in psoriatic lesions, compared to healthy control skin (Table 2).
Further analysis was performed to identify the cellular mechanisms that may be associated with the proteins 
that were detected in altered amounts in a proteomic approach, using the Ingenuity Pathway Analysis software 
(IPA). Diseases annotation revealed ‘psoriasis’ as the first hit when lesional and healthy (Table 3), or lesional and 
non-lesional differences (Table 3) were compared.
Annotation of biological functions by IPA highlighted ‘initiation of protein translation’ (Table 3) and ‘killing 
of Staphylococcus aureus’ as the main functions likely to be affected, respectively. Ingenuity canonical pathway 
screening identified the ‘role of IL-17A in psoriasis’ among the top ten most significant canonical pathways, when 
either lesional, or non-lesional protein expression was compared to healthy samples (Table 4). In addition, several 
cancer, neurological and neuromuscular canonical pathways were also highlighted.
Discussion
To expand knowledge about the pathomechanism of psoriasis, many extensive, large-scale comparative pro-
teomic approaches have been performed17,24,26. However, the comparison of healthy, non-lesional and lesional 
skin at the proteomic level has been missing from these studies. To fill this gap, our comparative proteomic anal-
ysis included healthy skin as well as non-lesional and lesional psoriatic samples.
Proteomic 
experiment
Group of 
donors Donors Age Gender
PASI 
score
No. 1.
Healthy
H I. 46
Male
n/aH II. 59
H III. 51
Plaque type 
psoriasis
P I. 65 17.1
P II. 63 9.9
P III. 50 5.5
No. 2.
Healthy
H IV. 23
Female
n/aH V. 48
H VI. 51
Plaque type 
psoriasis
P IV. 25 9.2
P V. 62 21.5
P VI. 70 17.5
No. 3.
Healthy
H VII. 37
Male
n/aH VIII. 39
H IX. 61
Plaque type 
psoriasis
P VII. 49 22.4
P VIII. 55 12.1
P IX. 61 12
Table 1. Basic demographic and clinical characteristics of donors involved in the proteomic analysis. (H: 
healthy donor, P: plaque-type psoriatic patient).
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Negative regulation of cell cycle
Positive regulation of cell cycle arrest
b
c
Biological processes II.
Expression related processes Response to stimulus
Viral process
Innate immune
response
Antigen processing and presentation
of exogenous peptide antigen
via MHC class I
Defense response
Immune system process
Stimulatory C-type lectin receptor
signaling pathway
Cellular response to interleukin-4
Defense response to fungus
Regulation of defense response
Neutrophil aggregation
Translation
Nuclear-transcribed mRNA catabolic process, 
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Nuclear-transcribed mRNA
catabolic process
RNA processing
Ribonucleoprotein complex
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RNA splicing
Formation of translation preinitiation complex
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Protein name Gene ID of protein Association with
psoriasis
Myb-Binding Protein 1A MYBBP1A novel
Protein PML PML known
DNA-Dependent Protein
Kinase Catalytic Subunit
PRKDC novel
Signal Transducer And
Activator Of Transcription 1
STAT1 known
d
e
Figure 2. Characterization of altered protein expression of lesional (L) skin compared to healthy (H) skin. 
Heatmap of relative expression of proteins differentially expressed in L and H skin (a, left column), and their 
expression in non-lesional (NL) and L skin (a, middle column) and NL and H skin (a, right column) (a). 
Biological processes for which proteins were differentially expressed in L and H are listed. The top ten processes 
are depicted for proliferation (b left, green circles), development (b right, blue circles), expression (c left, filled 
red circles) and response to stimulus (c right, orange circles). False detection rate (FDR) values are indicated 
with unfilled red circles around the filled circles for the various biological processes. The size of each circle 
is proportional to FDR values (unfilled circles) or to the number of proteins (filled circles). Four proteins 
differentially expressed in H and L skin are believed to participate in all four mechanisms of stress, immune 
response, proliferation and differentiation (d) and are listed in (e). (*Significant difference in relative protein 
expression at least by two-fold in L and H comparison).
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Protein name Gene ID ofprotein NL vs. L* L vs. H NL vs. H
Limma
(NL vs. L)
Rankprod
(NL vs. L)
Integrin alpha-7 ITGA7 2.983* 0.532 1.586 0.329 0.022
Plasmalemma vesicle-
associated protein PLVAP 2.284* 0.615 1.406 0.319 0.021
Cathepsin L2 CTSV¥ 2.431* 0.596 1.450 0.213 0.020
SWI/SNF-related matrix-
associated actin-dependent
regulator of chromatin
subfamily A member 5
SMARCA5 0.131* 1.768 0.232* 0.050 0.006
Collectin-12 COLEC12 2.842* 0.524 1.489 0.240 0.018
Skin-specific protein 32 XP32¥ 6.118* 0.262 1.601 0.010 0.005
Proactivator polypeptide-like 1 PSAPL1¥ 4.776* 0.300* 1.432 0.012 0.005
Integrin alpha-8 ITGA8 6.435* 0.222* 1.43 0.035 0.026
C-type lectin domain family 4
member K CD207
¥ 3.335* 0.387* 1.292 0.051 0.039
d
ABCA12 ITGA2 TOP1
AZU1 IVL TREX2
CD207 LCN2 XP32
CRABP2 LTF
DEFA1 MPO
EVPL NCAM1
FABP5 PI3
HMOX1 PSAPL1
HPSE S100A8
IL36G S100A9
Known psoriasis associated
trigger proteins 
Novel psoriasis associated 
trigger proteins
NCCRP1 ATP1B1 SYNM
RPL28 CNTN1
PRX MPZ
RPS11 VSNL1
ITGA8 RPL21
DDX21 PSME3
RPL23 SGCD
RPS15 MYH11
SLMAP RPS27
CSPG4 BCLAF1
e  f
Biological processes
Response to stimulus Development related processes
Multi-organism process
Symbiosis, encompassing mutualism through
parasitism
Cell-matrix adhesion
Epidermis development
Mesodermal cell differentiation
Cell adhesion
Extracellular matrix organization
System development
Tissue development
Formation of primary germ layerResponse to wounding
Innate immune response
Leukocyte migration
Chemotaxis
Sequestering of zinc ion
Response to stress
Neutrophil aggregation
Viral process
Immune system process
Defense response to fungus
b
c
Protein name Gene ID ofprotein NL vs. L* L vs. H NL vs. H
Limma
(NL vs. L)
Rankprod
(NL vs. L)
Protein function and
functional complexes
MICOS complex subunit
MIC25 CHCHD6 4.887* 0.248 1.213 0.281 0.014 MICOS complex
Charged multivesicular
body protein 5 CHMP5 0.293* 2.376 0.695 0.194 0.044 ESCRT-III complex
Collectin-12 COLEC12 2.842* 0.524 1.489 0.240 0.018 Scavenger receptor
Flotillin-2 FLOT2 2.043* 0.607 1.240 0.394 0.037 CSRM and CIE complex
Integrin alpha-7 ITGA7 2.983* 0.532 1.586 0.329 0.022 Cell surface receptor
LEM domain-containing
protein 2 LEMD2 2.163* 0.552 1.194 0.099 0.039
Nuclear lamina and
nuclear pore complexes 
Nucleolar protein 56 NOP56 0.390* 1.994 0.778 0.281 0.045 snoRNP complex
Plasmalemma vesicle-
associated protein PLVAP 2.285* 0.615 1.406 0.319 0.021 Endothelial diaphragm
Ras-related protein R-
Ras RRAS 2.293* 0.488 1.120 0.258 0.037 Lysosomal degradation
SWI/SNF-related matrix-
associated actin-
dependent regulator of
chromatin subfamily A
member 5
SMARCA5 0.131* 1.767 0.232* 0.050 0.006 Nucleosome remodelingfactor complex
Figure 3. Differential protein expression in lesional (L) and non-lesional (NL) skin and affected biological 
processes. Heatmap of relative expression for proteins differentially expressed in L and NL skin (a, left column) 
and the relative expression of these proteins NL and L skin (middle column) and L and healthy (H) skin (right 
column) (a). Biological processes for which proteins were differentially expressed in L and NL are listed. The 
top ten processes depicted to be affected in response to stimulus (b left, filled orange circles) and development 
(b right, filled blue circles). False detection rate (FDR) values are indicated with unfilled red circles around the 
filled circles for the various biological processes. The size of each circle is proportional to FDR values (unfilled 
red circles) or to the number of proteins (filled circles) (b). Proteins differentially expressed in L and NL but not 
in H and L are listed (c). Proteins for which the changes in NL and L compared to H are in different directions 
(increased vs. decreased and vice versa) are listed (d). Proteins that exhibited altered expression only in lesions 
(potentially trigger proteins) with known (e) and novel (f) association with psoriasis are listed. (*Significant 
difference in relative protein expression at least by two-fold in L and NL comparison).
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Protein description Gene ID of protein NL vs. H* L vs. H NL vs. L
Limma    
(NL vs. H)
Rankprod 
(NL vs. H)
Trifunctional purine 
biosynthetic protein 
adenosine-3
GART 4.451* 4.325 1.029 0.389 0.047
Guanylate-binding 
protein 1 GBP1
¥ 5.925* 4.745* 1.249 0.161 0.046
Kallikrein-10 KLK10¥ 6.549* 20.793* 0.315 0.060 0.047
Exportin-2 CSE1L 7.204* 5.799 1.242 0.253 0.024
Protein S100-A7 S100A7¥ 7.519* 14.74* 0.510 0.027 0.024
Unconventional myosin-
XVIIIa MYO18A 8.191* 14.777* 0.554 0.027 0.024
UDP-glucose 6-
dehydrogenase UGDH 10.175* 8.269* 1.231 0.027 0.024
SWI/SNF-related matrix-
associated actin-
dependent regulator of 
chromatin subfamily A 
member 5
SMARCA5 0.232* 1.767 0.131* 0.050 0.006
Figure 4. Differentially expressed proteins in non-lesional (NL) and healthy (H) skin. Proteins with expression 
that differs by at least 2-fold in non-lesional skin and healthy skin are listed (a). UGDH protein expression 
is similarly increased in NL and lesional psoriatic skin, compared to H controls. The highest difference in 
expression for NL and H was seen with immunohistochemical characterization of UGDH (n = 10), which 
indicated similar patterns of distribution in the three sample types. The strongest staining was observed in basal 
keratinocytes, and weaker staining was observed in the upper parts of the epidermis. Higher intensity staining 
UGDH was observed in non-lesional and lesional skin compared to healthy skin (b). A higher magnification of 
the epidermis is provided (c). (In merged figures, DAPI nuclear staining and UGDH are shown in blue and red, 
respectively; *: indicates statistical significance, ¥: indicates proteins with known association with psoriasis).
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In order to check the validity of our proteomic approach we compared major known psoriatic biomarkers 
published in previous genetic (genome-wide association studies)21, transcriptomic19,21,23 and proteomic stud-
ies17,18,20,22 with our proteomic dataset. Known psoriatic lesional biomarkers also found in our study includes 
AKR1B1016, CSTA17, FABP518, PI319, SCCA220, STAT116, STAT321, S100A718–20, S100A819,22 and S100A919,20,22,23. 
Moreover, annotation of diseases resulted in the identification of psoriasis with the strongest correlation based 
on differentially expressed proteins in either lesional vs. healthy or in lesional vs. non-lesional comparison. 
Canonical pathway analysis of non-lesional differences compared to healthy skin resulted in the identification of 
‘Role of IL-17A in Psoriasis’. However, these annotations also highlighted cancer, neurological, neuromuscular 
or muscular disease-related mechanism, suggesting their potential involvement in disease pathomechanism, or 
some similarities between these diseases.
Since our proteomic and in silico analysis cannot distinguish between cell-types, and provide information 
whether mechanistically linked alterations are taking place within the same, or different cell types, further exper-
iments are required in this direction to clarify the exact relevance of these predicted connections to psoriasis 
pathomechanism.
We performed literature a search for known functions of proteins found to be altered in amounts in our study 
to suggest mechanism through which they may potentially participate in the pathomechanism of the disease. The 
detected differences in the expression of proteins in healthy and lesional skin highlighted involvement in psoriasis 
of cell proliferation28, development29, response to stimulus30, expression31 related processes. In the comparison 
of non-lesional and lesional skin, we identified 56 proteins with differential expression, which represents only 
22.5% of the number of proteins which showed altered expression in the comparison of healthy and lesional skin 
(56 vs. 249). This highlights the importance of studying healthy skin in comparisons using patient samples for 
pinpointing disease-associated alterations. Qualitative literature-based analysis of these 56 proteins led to the 
identification of several mechanism for which association with psoriasis has already been described, including 
processes related to development29, response to stimulus26 and expression31.
Further analysis focused on gaining insight about the extent to which alterations are manifest in lesions and 
in non-lesional skin. Strikingly, nearly 80% of the 249 proteins exhibiting differential expression in lesional and 
healthy skin exhibited an intermediate expression level in the non-lesional skin, suggesting the possible pres-
ence of early, lesional-like alterations in non-lesional skin. Divergence from this trend was only observed for 
two small protein groups. Ten proteins — CHCHD6, CHMP5, COLEC12, FLOT2, ITGA7, LEMD2, NOP56, 
PLVAP, RRAS and SMARCA5 — differed in relative protein amounts in non-lesional and lesional skin, but the 
amounts of these proteins were similar in healthy and lesional samples. These ten proteins are likely to represent 
a group of non-lesional characteristic alteration. For nine proteins — CD207, COLEC12, CTSV, ITGA7, ITGA8, 
PLVAP, PSAPL1, SMARCA5 and XP32 — the direction of the expressional changes was different in non-lesional 
and lesional samples compared to healthy skin and might represent proteins that contribute to maintaining the 
non-lesional state.
Next, with the proteins in these two groups, we performed an extensive literature search to suggest potential 
mechanisms by which they may influence disease pathogenesis. Interestingly, all the identified proteins may play 
a role in signaling at different levels starting from the cell surface all away to the nucleus or mitochondria. The 
identified cell surface receptors include two integrins (ITGA7 and ITGA8) that are important in external signal 
recognition. Decreased ITGA7 levels — as observed in lesional vs. non-lesional skin — could be associated with 
delayed autophagy32, differentiation33 and increased migration34, all known to be affected in psoriatic lesions. In 
contrast, elevation of ITGA7 may induce growth suppression35. However, ITGA7 is characteristically expressed 
mainly by smooth muscle cells36 in the skin, suggesting that its involvement in keratinocyte related events are 
at least limited, or none. Instead, may suggest alterations in (vascular) smooth muscle cell adhesion-related 
processes37. Alternatively, ITGA7 may influence neurite outgrowth38. Therefore, further studies are required 
to confirm the observed TGA7 expression alteration and to identify the cell-types of source. Another identi-
fied cell-surface molecule, MYO18A, through recognizing microorganism lipopolysaccharides, may increase 
innate immune responses39 promoting cytokine production towards Th1 direction40; known to be important in 
psoriasis41.
Gene ID of protein L vs. H NL vs. H NL vs. L
AKR1B10 32.769* 25.318 0.773
CSTA 2.335* 1.752 0.75
FABP5 15.076* 4.678 0.31*
PI3 52.616* 4.105 0.078
S100A2 5.878* 2.527 0.43
S100A7 14.74* 7.519 0.51
S100A8 20.639* 5.234 0.254*
S100A9 19.679* 3.306 0.168*
SCCA2 35.468* 9.221 0.26*
STAT1 20.504* 14.478 0.706
STAT3 3.766* 2.309 0.613
Table 2. Detected expressional differences of classic protein biomarkers for psoriasis.
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Categories (L vs. H)
Diseases or disease related 
processes p-value
Predicted 
Activation 
State Activation z-score
Number of 
Proteins
Disease annotation of protein expressional differences between lesional (L) and healthy (H) skin
Dermatological Diseases and 
Conditions, Organismal Injury and 
Abnormalities
Psoriasis 6.89E-32 — — 61
Chronic psoriasis 2.15E-23 — — 27
Cancer, Cell Death and 
Survival, Organismal Injury and 
Abnormalities, Tumor Morphology
Cell death of osteosarcoma cells 4.04E-22 Decreased −4.899 24
Dermatological Diseases and 
Conditions, Organismal Injury and 
Abnormalities
Chronic skin disorder 7.47E-22 — — 28
Cancer, Cell Death and 
Survival, Organismal Injury and 
Abnormalities, Tumor Morphology
Cell death of cancer cells 4.24E-15 Decreased −4.64 33
Infectious Diseases
Viral Infection 1.89E-12 Increased 3.883 69
Replication of virus 3.58E-11 — 1.819 34
Replication of RNA virus 1.93E-10 — 1.799 31
Dermatological Diseases and 
Conditions, Organismal Injury and 
Abnormalities
Plaque psoriasis 4.05E-10 — — 15
Dermatological Diseases and 
Conditions, Immunological 
Disease, Inflammatory Disease, 
Organismal Injury and 
Abnormalities
Lichen planus 4.86E-10 — — 13
Categories (NL vs. L) Diseases or disease related processes p-value
Predicted 
Activation 
State
Activation z-score Number of Proteins
Disease annotation of protein expressional differences between non-lesional (NL) and lesional (L) skin
Dermatological Diseases and 
Conditions, Organismal Injury and 
Abnormalities
Psoriasis 3.72E-15 — — 21
Plaque psoriasis 1.78E-11 — — 10
Chronic skin disorder 3.06E-10 — — 10
Chronic psoriasis 8.58E-10 — — 9
Immunological Disease Allergy 8.57E-08 — — 12
Immunological Disease Hypersensitive reaction 1.30E-07 — — 12
Immunological Disease Immediate hypersensitivity 4.94E-07 — — 10
Dermatological Diseases and 
Conditions, Inflammatory 
Disease, Inflammatory Response, 
Organismal Injury and 
Abnormalities
Dermatitis 9.38E-07 — −1.067 11
Cardiovascular Disease, Organismal 
Injury and Abnormalities, Renal 
and Urological Disease
Ischemic acute renal failure 2.99E-06 — — 3
Organismal Injury and 
Abnormalities, Reproductive 
System Disease
Endometriosis 3.13E-06 — — 10
Categories (L vs.H) Biological Function p-value
Predicted 
Activation 
State
Activation z-score Number of Proteins
Biological function annotation of protein expressional differences between lesional (L) and healthy (H) skin
Protein Synthesis
Initiation of translation of 
protein 3.11E-46 — — 42
Translation 3.28E-40 — 0.737 57
Translation of protein 1.09E-38 — 0.555 55
Synthesis of protein 3.18E-36 Increased 2.691 64
Expression of protein 6.76E-36 — 0.527 57
RNA Damage and Repair Nonsense-mediated mRNA decay 3.06E-35 — — 32
Protein Synthesis Metabolism of protein 6.39E-31 Increased 2.92 85
Cell Death and Survival Necrosis 6.99E-18 Decreased −2.168 109
RNA Post-Transcriptional 
Modification Processing of RNA 4.39E-14 — −0.577 32
Cellular Movement Migration of cells 1.1E-12 Increased 2.067 83
Categories (NL vs. L) Biological Function p-value
Predicted 
Activation 
State
Activation z-score Number of Proteins
Continued
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FLOT242, CHMP543 and COLEC1244 participate in endocytic pathways, regulating the levels of cell-surface 
receptors and, thereby, signaling. FLOT2 is a known component of the raft microdomain complex that represents 
the major unit regulating STAT signaling pathways according to the raft-STAT signaling hypothesis45. The altera-
tion of FLOT2 expression could suggest a high relevance since STAT3 is a key regulator in psoriasis46. Reduction 
of the scavenger receptor COLEC12 could trigger psoriasis by trastuzumab treatment47. Moreover, COLEC12 
may influence the mitochondrial respiratory chain48, and this property is in agreement with the decreased level 
of mitochondrial MICOS complex subunit CHCHD649 observed in lesions compared to non-lesional skin. 
CHCHD6 regulates oxygen consumption and thereby may influence cell growth50. Reduced levels of CHCHD6 
were shown previously to lead to a shift from oxidative metabolism to glycolytic metabolism51 that negatively 
influences keratinocyte differentiation52, and both types of mechanisms are known to be affected in psoriasis53,54.
The altered expression of LEMD2 may suggest that signal transduction is also altered at the level of the 
nucleus. LEMD2, located in the inner nuclear membrane, regulates nuclear import/export processes55 and 
thereby intranuclear signaling50. During this regulation, LEMD2 is associated with the same complex as CHMP5, 
which was also identified in our studies. In the nucleus, the STAT-regulated protein NOP5656, a core protein of 
the box C/D small nucleolar ribonucleoprotein (snoRNP) complex, participates in the biogenesis of rRNAs57. 
Increased rRNA biogenesis is suggested to be necessary for high proliferation rate58, a process that is crucial for 
the development of psoriatic lesions.
Abnormal proliferation28, differentiation52 and, thereby, skin barrier function are key processes during pso-
riatic plaque formation. SMARCA5 is a component of the nucleosome remodeling factor complex59. Decreasing 
SMARCA5 levels are required for basal keratinocytes to shift form proliferation toward differentiation60. XP32 
is also a component of the epidermal differentiation complex61 and associated with skin barrier function62. The 
observed contrasting expressional differences of these two proteins in the non-lesional and lesional skin may 
contribute to our understanding of lesion formation and how non-lesional skin maintains its state.
Overall, our results indicate that dysregulation of cellular signaling — from signal detection, through endo-
cytosis of receptors and transduction of signal from the cell surface to the nucleus — may be affected during the 
disease. The alteration of these systems is likely to lead to increased reaction to external signals that could contrib-
ute to the maintenance of psoriatic plaques.
By comparing non-lesional and healthy skin, differential expression was observed for eight proteins (CSE1L, 
GART, GBP1, KLK10, MYO18A, S1007A, SMARCA5 and UGDH). Four of these proteins (CSE1L, GART, GBP1, 
UGDH) might be predisposing factors, as their expression was similar in non-lesional and lesional skin, and 
their significance would have been missed in comparisons for which healthy samples were not included. Of these, 
UGDH was detected with the highest relative difference. UGDH has not been highlighted previously in associ-
ation with psoriasis. We therefore decided to analyze it further. Immunohistochemical analysis confirmed our 
proteomic results: higher UGDH levels were found in non-lesional and lesional skin compared to healthy skin, 
that was mainly associated with keratinocytes. Elevated UGDH levels may increase chondrocytes proliferation 
indirectly, likely through increased hyaluronan production that binds different cytokines63. However, in vitro 
downregulation of UGDH and consequently decreased hyaluronan amounts did not influence keratinocyte pro-
liferation64. These results are in line with our observation, suggesting that elevated UGDH levels observed in 
non-lesional keratinocytes are not sufficient to modify their proliferation.
Categories (L vs. H)
Diseases or disease related 
processes p-value
Predicted 
Activation 
State Activation z-score
Number of 
Proteins
Biological function annotation of protein expressional differences between non-lesional (NL) and lesional (L) skin
Cell Death and Survival Killing of Staphylococcus aureus 8.53E-10 — −0.655 5
Cellular Movement,Immune Cell 
Trafficking Leukocyte migration 7.62E-08 — −0.509 18
Cell Death and Survival Killing of bacteria 1.10E-07 — −1.608 6
Cell-To-Cell Signaling and 
Interaction, Reproductive System 
Development and Function
Binding of gonadal cell lines 1.19E-07 — 1.964 6
Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking
Cell movement of leukocytes 1.55E-07 — −0.429 16
Cell Death and Survival Necrosis 2.20E-07 — −1.927 30
Antimicrobial Response, 
Inflammatory Response Antimicrobial response 2.42E-07 Decreased −2 10
Cell Death and Survival Killing of Staphylococcus aureus subsp. aureus 5.03E-07 — — 3
Cellular Movement, Hematological 
System Development and 
Function, Immune Cell Trafficking, 
Inflammatory Response
Cell movement of phagocytes 5.87E-07 — −0.902 13
Cellular Compromise, 
Inflammatory Response Degranulation of cells 6.21E-07 — −0.87 13
Table 3. Disease and biological function annotation of differentially expressed proteins.
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Proteins for which expression was affected only in lesions are often considered “trigger” proteins, as changes 
in the expression of these proteins are linked to the shift of the disease state. The proteins that have not previously 
been associated with psoriasis were categorized into two groups. The first group of proteins might contribute to 
the mechanosensitivity of the tissue (SGCD65, SYNM66, MYH1167, ATP1B168). The second group functions within 
the nervous system (MPZ, PRX69, CSPG470, CNTN1 and ITGA871, ATP1B172), could suggest the involvement of 
the peripheral nerve system in psoriasis73.
Finally, we searched for potentially central proteins in disease pathogenesis participating in key mechanisms 
of psoriasis including regulation of stress and immune response, proliferation and differentiation. Some of the 
identified proteins, such as PML74 and STAT175, have already been linked to psoriasis. We also identified two 
proteins, PRKDC and MYBBP1A, which have not previously been highlighted in context with the disease. The 
PRKDC may plays a role in the detection and repair of breaks in double-stranded DNA76 and mediates the phos-
phorylation of c-MYC77 and p5378 suggesting a potentially important role in psoriasis. The suggested altered 
expression by our results of the transcription factor MYBBP1A may also be among the potentially important 
proteins in psoriasis implicated in the pathogenesis since it functions as a co-repressor of NF-κB that may regulate 
responses to stress and cytokines79.
Taken together, our comparative proteomic approach of healthy, non-lesional and lesional skin led to the 
identification of various proteins which may function in psoriasis pathogenesis, providing a strong base for 
future studies. Proteins exhibiting opposite expression changes in lesional and non-lesional samples compared 
to healthy skin may function in the maintenance of the non-lesional stage and may represent future targets for 
therapeutic purposes.
Ingenuity Canonical Pathways (L vs. H) −log (p-value)
EIF2 Signaling 3.69E + 01
Regulation of eIF4 and p70S6K Signaling 1.95E + 01
mTOR Signaling 1.16E + 01
FAT10 Signaling Pathway 4.22E + 00
tRNA Charging 4.01E + 00
Role of IL-17A in Psoriasis 3.32E + 00
RAN Signaling 2.96E + 00
Intrinsic Prothrombin Activation Pathway 2.80E + 00
Polyamine Regulation in Colon Cancer 2.62E + 00
Neuroprotective Role of THOP1 in Alzheimer’s 
Disease 2.56E + 00
Ingenuity Canonical Pathways (NL vs. L) −log(p-value)
Caveolar-mediated Endocytosis Signaling 8.77E + 00
Paxillin Signaling 5.79E + 00
EIF2 Signaling 5.35E + 00
Virus Entry via Endocytic Pathways 4.51E + 00
IL-8 Signaling 4.41E + 00
Integrin Signaling 4.31E + 00
Agrin Interactions at Neuromuscular Junction 4.11E + 00
Regulation of eIF4 and p70S6K Signaling 3.88E + 00
NF-κB Activation by Viruses 3.68E + 00
mTOR Signaling 3.35E + 00
Ingenuity Canonical Pathways (NL vs. H) −log(p-value)
UDP-D-xylose and UDP-D-glucuronate 
Biosynthesis 3.10E + 00
5-aminoimidazole Ribonucleotide 
Biosynthesis I 2.92E + 00
Tetrahydrofolate Salvage from 
5,10-methenyltetrahydrofolate 2.70E + 00
Purine Nucleotides De Novo Biosynthesis II 2.36E + 00
Role of IL-17A in Psoriasis 2.29E + 00
Colanic Acid Building Blocks Biosynthesis 2.25E + 00
RAN Signaling 2.17E + 00
Intrinsic Prothrombin Activation Pathway 1.79E + 00
SPINK1 Pancreatic Cancer Pathway 1.66E + 00
MSP-RON Signaling Pathway 1.54E + 00
Table 4. Canonical pathways predicted to be affected in psoriasis based on detected expressional differences of 
proteins.
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Materials and Methods
ethics. Skin biopsy collection from donors, the procedure of collection and all experimental protocols were 
approved by the Regional and Institutional Research Ethics Committee and by the Human Investigation Review 
Board of the University of Szeged (SOEDAFN-002, IF-562-5/2016 and IF-15056/2015; 157/2015; 3638 and 2799, 
3517), strictly following the guidelines and regulations of the Declaration of Helsinki. Prior to surgical interven-
tion and following a detailed description of the skin biopsy donation procedure, participants provided written 
informed consent. No donor under the age of 18 was included in our study.
criteria for inclusion of patients in the study and skin sample collection. To identify alterations 
that are general in chronic plaque psoriasis and keep the number of volunteers for skin biopsy collection to a 
minimum, for our proteomic approach, we randomly engaged individuals (I) of different age to minimize pos-
sible age-related differences; (II) with various Psoriasis Area Severity Index (PASI) scores between 5 and 25, 
since the score for an individual patient varies over time and with relapse; (III) of both genders to avoid possible 
gender-associated differences; and (IV) with both early and late onset. A total of 9 (3 × 3) patients suffering from 
chronic plaque psoriasis and the same number of healthy donors were involved in our study. The data of individ-
uals involved in the study are summarized in Table 1. All psoriatic patients had not received any kind of treatment 
for the condition for at least 6 months. The 6 mm skin punch biopsies containing the epidermis and the dermis 
were collected from an area of the upper-middle gluteal region that is not exposed to sunlight. Both lesional and 
non-lesional samples were collected from patients. Non-lesional samples were taken at least 7 cm from the edge 
of the lesion subjected for biopsy. The presence of psoriasis was clinically verified for all patients, and clinical as 
well as demographic data of the donors are presented in Table 1.
comprehensive and comparative proteomics of healthy, non-lesional and lesional skin. Sample 
preparation from skin biopsy and sequential protein extraction. Samples were cut with a razor blade. Skin proteins 
were extracted sequentially in four consecutive solubility-based extraction steps. Extraction buffers were used in 
increasing order of their solubilizing properties for a better separation of proteins. Samples were initially incubated 
in extraction buffer I. (0.15 M NaCl, 50 mM Tris-HCl, pH 7.4) for 24 h at 4 °C in the presence of protease inhibi-
tors. Protein extracts were then clarified by centrifugation and separated from the pellet. This step was repeated 
by resuspending the pellet in extraction buffer II, which contained 1 M NaCl, 25 mM EDTA, 50 mM Tris-HCl, pH 
7.4. Following extraction with 250 mM SDS-containing extraction buffer III (8 h at room temperature), guanidine 
hydrochloride containing extraction buffer IV (4 M GuHCl, 10 mM EDTA, 50 mM Tris-HCl, pH 7.4) was applied 
for 48 h at 4 °C. The same protein extracts of the three donors were pooled in each investigated group (healthy, 
non-lesional, lesional). Extraction procedure was carried out three times and each contained extracted proteins of 
three donors following the pooling of the samples which were than subjected for downstream proteomic analysis.
Protein identification by 2D LC-MSMS. A total 35 µg protein from each sample was applied for mass spectrom-
etry analysis. A modified filter-aided sample preparation method was used for tryptic digestion of the protein 
extracts80. High-pH reversed-phase chromatography was performed on a C18 column (Phenomenex, Kinetex 5 µ 
EVO C18 100 A, 2.1 × 100 mm; cat. no. 00D-4622-AN, flow rate: 150 µl/min). Forty-eight fractions were collected 
from 1 to 25 minutes (half minute/fraction) and 4-4 fractions were combined (1,13,24,37; 2,14,25,38 and so on) 
to get 12 final fractions. Each fraction was subjected to nano LC-MSMS analysis on an Orbitrap Elite hybrid mass 
spectrometer (Thermo) coupled with a Waters nanoAcquity UPLC system, using a gradient elution after trapping 
the samples onto the trap column. Data-dependent analyses were applied; the 20 most intense peaks were selected 
for ion-trap collision-induced dissociation after each survey scan measured in the Orbitrap. Proteome Discoverer 
(ver.: 1.3) was used to generate MS/MS peak-list files and our in-cloud ProteinProspector (ver.: 5.16.0) database 
search engine was used for protein identification against the human sequences from the UniProtKB.2015.12.14.
random.concat (149781/55820795 entries searched) database. Detailed protocols and applied counting for semi-
quantitative analysis is described as Supplementary Information.
Immunofluorescence staining of skin sections for UGDH. For immunofluorescence analysis, 5 µm sec-
tions of frozen embedded skin biopsies from psoriatic patients (non-lesional and lesional skin) and healthy indi-
viduals were used. After fixation and permeabilization (Foxp3 staining buffer set, fixation/permeabilization kit, 
Miltenyi Biotec, used according to the description of the manufacturer), samples were blocked in Tris-buffered 
saline (TBS) containing 1% bovine serum albumin (BSA) and 1% normal goat serum (NGS) for 1 h at room temper-
ature. Samples were incubated overnight at 4 °C in TBS with 1% NGS and primary antibodies against UGDH (rabbit 
polyclonal antibody, ab155005, Abcam), diluted to 1:100. Following washing in TBS, AF546 secondary antibodies 
(Goat anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 546, A-11035, Invitrogen), 
diluted in TBS containing 1% NGS to 1:500, were applied for 1 h at room temperature.
Literature search to identify novel psoriasis-associated proteins. To identify proteins not yet linked 
with the pathomechanism of psoriasis, literature mining was carried out using protein names or the encoding 
gene’s HUGO Gene Nomenclature Committee (HGNC) symbol(s), applying the following strategy: each protein 
or gene name was searched together with “psoriasis” as a keyword using the RISmed R package.
Statistical analysis. To compare protein abundance from healthy, lesional and non-lesional skin extracts, 
significant differences were determined based on relative peptide ion chromatograms and spectrum counting 
and evaluated using two different approaches: (1) modified t-test (limma) and (2) rank product test (as described 
by Schwämmle et al.81) following t-test. We considered a protein amount to be different between two samples if 
at least one of the three tests were significant (test <0.05) and the absolute fold change was at least two or higher.
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Purpose: Our goal was to study whether glycerol and xylitol provide protection against
osmotic stress in keratinocytes.
Methods: The experiments were performed on HaCaT keratinocytes. Hyperosmotic stress
was induced by the addition of sorbitol (450, 500 and 600 mOsm). Both polyols were applied
at two different concentrations (glycerol: 0.027% and 0.27%, xylitol: 0.045% and 0.45%).
Cellular viability and cytotoxicity were assessed, intracellular Ca2+ concentration was mea-
sured, and the RNA expression of inﬂammatory cytokines was determined by means of PCR.
Differences among groups were analyzed with one-way ANOVA and Holm-Sidak post-hoc
test. When the normality test failed, Kruskal–Wallis one-way analysis of variance on ranks,
followed by Dunn’s method for pairwise multiple comparison was performed.
Results: The higher concentrations of the polyols were effective. Glycerol ameliorated the
cellular viability while xylitol prevented the rapid Ca2+ signal. Both polyols suppressed the
expression of IL-1α but only glycerol decreased the expression of IL-1β and NFAT5.
Conclusions: Glycerol and xylitol protect keratinocytes against osmotic stress. Despite their
similar chemical structure, the effect of these polyols displayed differences. Hence, joint
application of glycerol and xylitol may be a useful therapeutic approach for different skin
disorders.
Keywords: hyperosmotic stress, glycerol, xylitol, intracellular calcium concentration
Introduction
Local hyperosmotic condition is revealed to be associated with several inﬂamma-
tory disorders (eg, corneal inﬂammation in dry eyes syndrome, inﬂammatory bowel
disease, etc.).1 Presumably, a local hyperosmotic challenge may contribute to the
development of irritant contact dermatitis (ICD). ICD is a non-immunologic, non-
speciﬁc inﬂammatory skin disease induced by physical, mechanical or chemical
factors and accompanied by impaired barrier function. This results in increased skin
permeability and transepidermal water loss (TEWL).2 Water evaporation can lead to
a higher osmotic pressure in the superﬁcial layer of the skin. Furthermore, hyper-
osmolarity induces various intracellular responses in different types of cells and
reduces cellular viability.3–7 It has been described that a hyperosmotic stimulus
elevates intracellular calcium (Ca2+) concentration in HaCaT keratinocytes.6,8
Although its exact molecular mechanism has not yet been revealed, it has been
shown that Ca2+ is derived from both intra- and extracellular compartments.6,8
Keratinocytes are known to produce pro-inﬂammatory cytokines when exposed
to osmotic stress.9 At mRNA level, expression of tumor necrosis factor-alpha
(TNF-α), interleukin 1-beta (IL-1β), IL-8,3 IL-64 and nuclear factor of activated
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T cells 5 (NFAT5)5 was found to be higher in epithelial
cells. In normal human epidermal keratinocytes, elevated
mRNA expression of TNF-α, IL-1β, IL-6 and IL-8 was
observed.9
NFAT5 is a principal transcription factor involved in
water homeostasis during normal corniﬁcation10 and acti-
vated by hyperosmotic stress;5 however, its regulation by
Ca2+ signals is equivocal.11–13 Local hyperosmotic stress of
the skin activates NFAT5 in macrophages1 thereby intensify-
ing the electrolyte clearance via lymphatic vessels.14
Under experimental conditions, different methods are
used to induce hyperosmotic stress. Sodium chloride is
usually used for this aim3–5 and non-ionic organic agents
such as sorbitol9 and sucrose4 can also be applied on
keratinocyte cultures.
Glycerol and xylitol have well-known beneﬁcial effects
on the skin15–18 but their role as osmolytes has not yet been
fully clariﬁed. It has been revealed that glycerol composes
the principal osmolyte system of several bacterial species19
while xylitol inhibits inﬂammatory cytokine expression.20
Previously, we have shown the anti-inﬂammatory and anti-
irritant effects of glycerol and xylitol.16–18 Other in vitro
experiments have revealed that glycerol suppresses human
leukocyte antigen-DR (HLA-DR) mRNA level and xylitol
upregulates ﬁlaggrin mRNA expression.21
The aim of the present study was to investigate
whether glycerol and xylitol provide protection against
hyperosmotic stress in vitro. Their effects on cellular via-
bility and cytotoxicity, intracellular Ca2+ concentration,
expression of pro-inﬂammatory cytokines and cellular via-
bility were studied.
Materials and methods
Cell culture
HaCaTcells kindly provided byDr N. E. Fusenig (Heidelberg,
Germany) were cultured in Dulbecco’s modiﬁed Eagle’s med-
ium containing 4.5 g/L glucose, 1.8 mM Ca2+ (DMEM-HG)
supplemented with 10% fetal bovine serum (FBS), 2 mM
L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin,
0.25 µg/mL amphotericin B and grown at 37°C in a humidiﬁed
atmosphere containing 5% CO2. Three to four days after plat-
ing, cells were collected from semi-conﬂuent cultures by 5–10
mins trypsinization (0.25% trypsin-EDTA solution). The pro-
teolic digestion was stopped by FBS and the cells were sedi-
mented (10 mins, 4°C, 1,500 g) and resuspended in the
medium for further use. Cellular viability was determined by
the trypan blue exclusion test. The experiments were per-
formed on cultures, where trypan blue was excluded from
95% of the cells.
Preparation of the treating media
For osmolarity measurement, Model 5600 Vapro®
Vapor Pressure Osmometer (Dieren, The Netherlands)
was used. The basal osmolarity of the serum-free
DMEM-HG medium was 338 mOsm. Media contained
3 or 30 mM polyols, respectively, which was equivalent
to 0.027 or 0.27 w/w% glycerol and 0.045 or 0.45 w/w
% xylitol.21 The osmolarity of these solutions was also
measured. The ﬁnal osmolarity of 450, 500 and 600
mOsm was reached by the addition of the appropriate
amount of 1.83M sorbitol stock solution. Serum-free
DMEM-HG media containing only glycerol, xylitol or
sorbitol in concentrations mentioned above, respectively,
were also applied.
Cellular viability and cytotoxicity
Cells were seeded into 96-well culture plates at
a density of 104 cells/well in DMEM-HG supplemented
with the appropriate agents detailed above, and serum-
starved 24 hrs before any treatments. For 60 mins, cells
were incubated with or without 0.27% glycerol or
0.45% xylitol in serum-free DMEM-HG, followed by
incubation with 450, 500 or 600 mOsm culture medium
with or without 0.27% glycerol or 0.45% xylitol for
24 hrs. Experiments were carried out in triplicates, and
data are presented as the means of three experiments.
For the cell viability assay, 0.5% MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) solution was added to the cells at 37°C for 4 hrs,
and then the formazan crystals were solubilized and the
optical density (OD) was measured at 540 nm by
a Multiscan Ex spectrophotometer (Thermo Labsystems,
Beverly, Massachusetts, USA) and Ascent Software
(Thermo Fisher Scientiﬁc, Waltham, Massachusetts,
USA). The absorbance rate was compared to untreated
samples and represented as percentage rate of living cells.
Cytotoxicity was assessed by using the Cytotoxicity
Detection Kit PLUS (Roche Diagnostics, Risch,
Switzerland) according to the manufacturer’s instructions.
Brieﬂy, released lactate dehydrogenase (LDH) was quan-
tiﬁed from the supernatant by a colorimetric method and
optical density was measured at 492 nm. Measured values
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were corrected with the background values of the cell-free
culture medium. Results are presented of % in cytotoxi-
city, where lysed cells correspond to 100% cytotoxicity.
Determination of changes in [Ca2+]i
HaCaT keratinocytes were plated onto 13 mm diameter
uncoated sterile coverslips (VWR, Radnor, Pennsylvania,
USA) and were left to attach and proliferate for 24 hrs.
Coverslips with the attached cells were transferred and
incubated in Tyrode’s solution (144 mM NaCl, 0.4 mM
NaH2PO4, 4 mM KCl, 0.53 mM MgSO4, 1.8 mM CaCl2,
5.5 mM glucose and 5 mM HEPES, pH=7.4). HaCaT cells
were loaded by incubation for 20 mins with the acetoxy-
methyl ester (AM) form of a single wavelength calcium-
sensitive ﬂuorescent dye (Fluo-4, Molecular Probes Inc.,
Eugene, Oregon, USA, 5 μM from a stock of 1 mM in
DMSO +20% pluronic acid Pluronic F-127 Sigma-
Aldrich, Saint Louis, Missouri, USA and 6.25 nM/mL
Probenecid, Molecular Probes Inc., Eugene, Oregon,
USA) at room temperature in dark. After incubation per-
iod, the cells were washed in indicator-free Tyrode’s solu-
tion to remove any dye. The technique for intracellular
calcium detection was based on established procedures
described earlier.22 Subsequently, cells were incubated
for 30 mins with 0.027% or 0.27% glycerol and 0.045%
or 0.45% xylitol21 in Tyrode solution, respectively.
Optical measurements were performed using a Zeiss
Axiovert 100 microscope (Zeiss, Oberkochen, Germany)
equipped with a xenon lamp and used in epiﬂuorescent
mode at 100x magnitude. The coverslips were placed into
a low volume imaging chamber (Warner Instruments,
Hamden, Connecticut, USA) (37°C) at the microscope stage
and cells were superfused with Tyrode alone for at least 10
mins (control period). Hyperosmotic stimulus was added to
the cells in rapid perfusion (2–3 µL/sec) of 450 mOsm sorbi-
tol, followed by the addition of 30 nmol/mLA23187 ionophor
in Tyrode. Cells in the 75×75 µm frame were illuminated at
485 nm and the emitted light was recorded at 535 nm. Images
of relative ﬂuorescence intensity of a cell group (3–5 cells/
group) were collected in 8–10 independent experiments per
treatment group with the Mintron 7266pd Color CCD Camera
(New Taipei City, Taiwan). Raw data were analyzed with
WinWCP V4.5.0 (Glasgow, Scotland) and Clampﬁt 10.6
(San Jose, California, USA) softwares.
Calibration was performed by the [Ca2+]i = Kd
(F-Fmin)/(Fmax-F) method23 where [Ca2+]i is the intracel-
lular Ca2+ concentration, Kd is the dissociation constant
(345 nM), F is the ﬂuorescence intensity evoked with the
hyperosmotic stimulus, Fmin values were developed from
corrected ﬂuorescence intensity before osmotic stress and
Fmax values were derived from the maximal ﬂuorescent
response after the addition of the ionophor solution.
Background correction was calculated with the autoﬂuor-
escence of unloaded cells and the decrease of ﬂuorescence
intensity in untreated cells caused by bleaching or dye
efﬂux. For representative ﬁgures, ΔCa2+ = ΔF/F = (F −
Frest)/Frest) was calculated.23
Real-time polymerase chain reaction
(RT-PCR)
Cells were seeded into 6-well plates at a density of 2×105
cells/mL and serum-starved overnight. Cells were pre-
incubated for 60 mins with 0.27% glycerol or 0.45%
xylitol, followed by incubation with 450 mOsm sorbitol
for 2 and 6 hrs.3–5 Untreated or sorbitol-treated cells
served as negative or positive controls, respectively.
Total RNA was isolated using TRIzol reagent (Sigma-
Aldrich, Saint Louis, Missouri, USA) according to the
manufacturer’s instructions. To avoid DNA contamination,
DNAse treatment was performed and intron-spanning
assays were used. cDNA was synthesized from 1 µg total
RNA using the iScript cDNA Synthesis Kit (Bio-Rad
Laboratories, Hercules, California, USA). Real-time RT-
PCR experiments were carried out with the Universal
Probe Library system (Roche Diagnostics, Risch,
Switzerland) using TaqMan probe-based assays and
a C1000 Touch Thermal Cycler (Bio-Rad Laboratories,
Hercules, California, USA). The applied primers are listed
in Table 1. The expression of each gene was normalized to
the 18S rRNA gene, and relative mRNA levels were
calculated by the ΔΔCt method, compared to untreated,
time-matched control samples.
Statistical analysis
Data analysis was performed with SigmaStat for Windows
11.0 software (Jandel Scientiﬁc, San Rafael, California,
USA). Differences among groups were analyzed with one-
way ANOVA and Holm-Sidak post-hoc test and data are
presented as mean (m) values with standard deviation
(SD). When the normality test failed, Kruskal–Wallis one-
way analysis of variance on ranks, followed by Dunn’s
method for pairwise multiple comparison was performed.
In such cases, median values (M) with 25th and 75th
percentiles (25p and 75p, respectively) are given. P<0.05
was considered statistically signiﬁcant.
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Results
Glycerol of 0.27% but not xylitol
ameliorated the viability of HaCaT cells
exposed to hyperosmotic stress
During a period of 24 hrs, osmotic stresses of 450 and 500
mOsm did not inﬂuence cellular viability, and the average
cytotoxicity values were negligible. However, 600 mOsm
sorbitol signiﬁcantly reduced viability. The reduction was
also considerable in the additional polyol-treated groups,
but glycerol treatment resulted in signiﬁcantly higher via-
bility as compared to the positive control (DMEM-HG
+600 mOsm sorbitol) group. 0.45% xylitol failed to
improve the survival of the cells. The average cytotoxicity
value of the 0.27% glycerol +600 mOsm sorbitol-treated
group was somewhat lower but did not differ signiﬁcantly
from that of its control (DMEM-HG+600 mOsm sorbitol)
group. Viability and cytotoxicity in groups exposed to
0.27% glycerol and 0.45% xylitol alone did not differ
signiﬁcantly from that of their matched DMEM-HG con-
trol group (Figure 1A, B).
Xylitol of 0.45% provides protection
against the hyperosmotic
stimulus-induced increase in intracellular
Ca2+ concentration
Hyperosmotic stress induced by 450 mOsm sorbitol was
accompanied by a short elevation of intracellular Ca2+
concentration. This elevation (M=328.6 nM, 25p=232.0,
75p=602.4) was prevented neither by glycerol nor the
lower concentration of xylitol, but it was suppressed by
the higher concentration (0.45%) of xylitol (M=78.76 nM,
25p=45.92, 75p=140.72) (Figure 2A). Figure 2 also shows
Table 1 Known sequences of primer pairs and probes used for RT-PCR
Sense Antisense
TNF-α CAGCCTCTTCTCCTTCCTGAT GCCAGAGGGCTGATTAGAGA
IL-1α AACCAGTGCTGCTGAAGGA TTCTTAGTGCCGTGAGTTTCC
IL-1β AAAGCTTGGTGATGTCTGGTC AAAGGACATGGAGAACACCACT
IL-6 CAGGAGCCCAGCTATGAACT GAAGGCAGCAGGCAACAC
NFAT5 TCAGACAAGCGGTGGTGA AGGGAGCTGAAGAAGCATCA
IL-8 TaqMan® Gene Expression Assay, Thermo Scientiﬁc
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Figure 1 (A) The effects of glycerol and xylitol on cellular viability in hyperosmotic stress. (B) The effects of polyols in osmotic stress-induced cytotoxicity. Statistical
analysis was performed with one-way ANOVA and Holm-Sidak post-hoc test (mean+SD), *p<0.05 vs DMEM-HG., #p<0.05 vs DMEM-HG +600 mOsm sor, n=3.
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two representative curves of this response from the sorbi-
tol-treated (Figure 2B) and the sorbitol and 0.45% xylitol-
treated groups (Figure 2C).
Polyols prevented the elevation in the
mRNA expression of inﬂammatory
cytokines and NFAT5 induced by osmotic
stress
The mRNA expression of inﬂammatory cytokines (TNF-α,
IL-1α, IL-1β, IL-6 and IL-8) and the osmosis-related
NFAT5 was measured after 2 and 6 hrs hyperosmotic
stress. After 6 hrs, no signiﬁcant changes were detected
(data not presented). Following 2 hrs treatment, the cyto-
kine levels of glycerol or xylitol-treated groups were simi-
lar to that of the untreated control group. 450 mOsm
sorbitol induced considerable increase in IL-1α, IL-1β,
IL-8 and NFAT5 expression. Both 0.27% glycerol and
0.45% xylitol prevented the elevation in the expression
of IL-1α (Figure 3A). Furthermore, both 0.27% glycerol
and 0.45% xylitol led to considerably lower expression of
IL-8, and the expression levels did not differ signiﬁcantly
from those of untreated control group (Figure 3D). As
concerns IL-1β and NFAT5, only 0.27% glycerol dimin-
ished considerably their expression (Figure 3B, C). No
signiﬁcant difference was found among the six study
groups in TNF-α and IL-6 expression (data not shown).
Discussion
ICD is a frequent occupational disorder24 which is character-
ized by impaired barrier function leading to increased TEWL.
Water evaporation exposes keratinocytes to a condition of high
osmotic pressure.9 In our previous animal experiments,
sodium lauryl sulfate (SLS)-induced skin irritation resulted
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in the reduction of epidermal thickness17 that can be consid-
ered as an indirect evidence for osmotic stress. Thus, the
present study aimed at the investigation of osmotic challenge
potentially accompanying ICD. In response to hyperosmotic
stress, organic osmolytes are accumulated by the cells. In the
skin, betaine, myoinositol and taurine are important osmolytes
and the expression of their transporters (betaine/GABA trans-
porter, sodium/myoinositol transporter and taurine transporter)
is induced by osmotic stress.25
The anti-irritant and anti-inﬂammatory effects of glycerol
and xylitol have already been demonstrated in animal
experiments.17 Joint application of glycerol and xylitol
increases skin hydration, decreases TEWL, improves biome-
chanical properties of the skin and induces a higher ﬁlaggrin
production in the epidermis after 2 weeks of application.18
However, their cellular mechanism of action has not been
revealed in details. We assumed that these polyols may act as
organic osmolytes and therefore may have a role in
osmoregulation.
It has been described that the effects of polyols may
depend on the applied concentration.17,26 Hence, two differ-
ent concentrations were tested in our in vivo studies16,17 and
also two different concentrations were chosen for the present
experiments, based on previous in vitro results.21 According
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Figure 3 In vitro effects of polyols on (A) IL-1α, (B) IL-1β, (C) NFAT5 and (D) IL-8 expression. The expression of each gene was normalized to the 18S rRNA gene and relative
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to the results of the effect of polyols on Ca2+ concentration
in our preliminary experiments, only the higher polyol con-
centrations were applied in the measurement of cellular
viability, cytotoxicity and cytokine expression.
In order to induce osmotic stress, instead of the ionic
sodium chloride and the detergent SLS, sorbitol was cho-
sen, which is a metabolically inactive, inert agent. Sorbitol
is also a polyol osmolyte such as glycerol and xylitol;
however, it has no known protective effect in inﬂammatory
skin conditions, and it is used to induce osmotic stress.8
Osmotic challenge inﬂuences cellular viability in an
osmolarity- and time-dependent manner.4–7 Such effect is
also characteristic of ICD: severe irritation of the skin (24
hrs exposure to SLS) can induce tissue necrosis in vivo27
but milder irritant challenges do not lead to necrosis.28 In
our experiments, 24 hrs exposure to 450 and 500 mOsm
sorbitol did not inﬂuence cellular viability and cytotoxi-
city, but 600 mOsm resulted in a signiﬁcant decrease in
viability as compared to untreated control cells.
However, instead of 600mOsm, 450mOsm osmotic stress
was applied to measure intracellular calcium concentration, in
order to examine the protective effects of polyols, with the
elimination of cell death. According to our pilot study, 450
mOsm hyperosmotic stimulus with sorbitol was sufﬁcient to
induce a short elevation of intracellular Ca2+ with a kinetics
similar to that of measured by Dascalu et al who applied 500
mOsm sucrose.6 Although the exact molecular mechanism is
still not fully clariﬁed, it has been described that dihydropir-
idine-sensitive Ca2+ channels are not affected.6 The transient
receptor potential vanilloid 1b (TRPV1b) non-selective cation
channel, which is expressed also by HaCaT cells,29 can be
induced by cell shrinking in hypertonicity30 and therefore may
have a potential role in Ca2+ response. In osmotic stress,
increased inositol 1,4,5-trisphosphate (IP3) and diacyl-
glycerol (DAG) synthesis were observed, as well.31 TRPV1
can also be activated by Ca2+32 and DAG.33 Moreover, IP3
receptors may contribute to Ca2+ inﬂux, too.34
Based on literature data,21 the applied polyols alone did
not inﬂuence intracellular Ca2+ concentration. According
to our results, xylitol prevented the elevation of intracel-
lular Ca2+ concentration induced by the hyperosmotic
sorbitol solution while glycerol did not inﬂuence this para-
meter. Further investigations are necessary to reveal the
reason for this difference and the exact mechanism via
which xylitol inhibits Ca2+ signal.
In addition to the rapid Ca2+ response, the applied
osmotic challenge has longer effects, as well. 2 hrs of
exposure to 450 mOsm sorbitol increased the expression
of IL-1α, IL-1β and IL-8 in HaCaT cells. It has been
described that cytokine expression elevates in keratinocytes
when 500 mOsm of osmotic stimulus is present for 6 hrs.9
Cytokine production may originate from the Ca2+
response.35 However, in a recent study, pro-inﬂammatory
responses evoked with ATP- or bradykinin-induced eleva-
tion of the intracellular Ca2+ concentration could not be
suppressed by glycerol or xylitol. Moreover, none of these
polyols inﬂuenced the subcellular translocation of the Ca2+-
dependent protein kinase C (PKC)α. However, xylitol but
not glycerol translocated the Ca2+-independent PKCδ.36
TRPV1 activation can also lead to enhanced cytokine pro-
duction via direct or indirect NF-κB activation.37
Independently from the Ca2+ response, hyperosmotic stress
also activates the transcription factor NFAT55 which regu-
lates TNF-α38 and can bind the promoter of IL-1 and IL-6.1
Thus, elevated expression of NFAT5 might have contributed
to the increased cytokine expression in the present study.
Our previous in vivo investigations have already shown the
anti-inﬂammatory effect of glycerol and xylitol.16–18
However, differences can be found as compared to the
present in vitro results. Glycerol and xylitol decreased the
mRNA expression of IL-1β and TNF-α, but had no effect
on the IL-1α levels in a murine model of ICD.17 Several
factors may explain the beneﬁcial effects of polyols on
cytokine expression. In addition to the prevention of Ca2+
signal and the inhibition of NFAT5 expression, glycerol and
xylitol may affect the inﬂammatory process via stabilizing
protein structure. As chaperon osmolytes, these polyols are
able to enhance protein folding, thereby assisting in the
development of the ﬁnal structure essential for the optimal
enzyme function, and they promote protein–protein and
protein–DNA interactions.39
Our ﬁndings indicate that glycerol provides protection
not only against acute inﬂammation but also against a more
serious damage which occurs after a relatively longer time-
span. The protective effect of glycerol was found to appear
after a 24 hrs exposure to osmotic stress when aquaporin-3
(AQP-3) gene expression shows a peak.40 If AQP-3 expres-
sion increases at protein level, as well, it provides an
enhanced intracellular transport of glycerol. This theory is
supported by our observation that cellular viability was
ameliorated only when glycerol was continuously available
(data not shown).
Conclusion
The effects of glycerol and xylitol were tested under
hyperosmotic condition as an in vitro model of osmotic
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stress accompanying ICD and other xerotic skin diseases.
The applied polyols supported cell viability, prevented
hyperosmosis-induced Ca2+ signal and the expression of
inﬂammatory cytokines. Despite their similar chemical
structure, the effect of these polyols displayed differences
(Table 2). Hence, joint application of glycerol and xylitol
may be a useful therapeutic approach for different skin
disorders.
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